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1. INTRODUCTION 
 
    Infectious diseases in South East Asia are associated with a high mortality and morbidity. 
The estimated deaths due to major preventable infections in children in South Asia were over 
two thirds of the total 3.7 million deaths. Despite advances in the field of medicine the 
inability in timely recognition of the various infectious syndromes, inappropriate use of 
antibiotics and the inappropriate interpretation of various serological tests are major players 
(1, 2). Lack of appropriate microbiological facilities and the high costs involved also play a 
major role in the rampant use of empirical antibiotics (3). 
Severe community acquired infections that require admissions to intensive care unit (ICU) 
are associated with high morbidity and mortality. Prompt and accurate diagnosis of the 
infectious syndrome helps in initiating the appropriate therapy. The outcomes in these 
patients is determined by various factors, such as the disease itself, severity of the infection 
as evidenced by organ system dysfunction, Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score, initiation of appropriate antibiotics and co-morbidities.  
The data that we have on the clinical spectrum of the cohort of patients with severe 
community acquired infections in India is very sparse. Information regarding the clinical 
correlates and factors that contribute to the morbidity and mortality of this treatable disease 
is lacking. This study examines patients with severe acute community acquired infections 
warranting intensive or high dependency care with regard to the clinical spectrum of 
common infectious syndromes, the clinical outcome with reference to morbidity and 
mortality, implications of co-existing co morbidities on the outcome and to identify the risk 
factors associated with a poor outcome. It is also evident that in patients with severe 
infections, accurate diagnosis at admission and the initiation of appropriate specific therapy 
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and supportive therapy can alter the end result. We will therefore examine the admission 
diagnosis and treatment initiated and the impact it has on the outcome of  patients with 
severe community acquired infections.  
Thus we hope that we have a better clinical and evidence based understanding of severe 
community acquired infections in the Indian population, in order to aid in making accurate 
clinical diagnosis, initiate appropriate therapy and identify potential reversible risk factors. 
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2. AIM 
To understand the clinical spectrum, etiology and outcome of community acquired infections 
requiring admission into Medical Intensive Care Unit and Medical High Dependency Unit 
presenting to the Department of General Medicine at Christian Medical College, a tertiary 
care hospital in South India. 
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3. OBJECTIVES 
 
1. To determine the etiological and clinical spectrum of severe community acquired 
infections requiring ICU care. 
 
2. To determine the admission correlates of etiological diagnosis. 
 
 
3. To determine factors that determine clinical outcome including clinical severity score 
(APACHE), etiology, clinical co morbidities and choice of treatment, 
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4. REVIEW OF LITERATURE 
4.1 INFECTION- EPIDEMIOLOGY 
       Infection is a microbial phenomenon which is characterized by an inflammatory 
response to the presence of micro-organisms or the invasion of normally sterile host tissue 
by those organisms (4). 
The infection could either be a mild or a severe one. In order to help clinicians ascertain the 
severity of an infection various terms were introduced and defined by critical care 
specialists. 
4.2 SEVERITY OF THE INFECTION 
4.2.1 SYSTEMIC INFLAMMATORY RESPONSE  
Systemic inflammatory response (SIRS) is a clinical syndrome that defined a state of 
dysregulated inflammation. This terminology was applicable to both infectious and non-
infectious processes (5). 
For simplicity SIRS is defined by four variables namely:  
 Temperature: >38 deg C or < 36 deg C 
 Heart rate : > 90 beats per minute  
 Respiratory rate: >20 breaths per minute or PaCO2 < 32 mmHg 
 White blood cell count: > 12,000/ cu mm or < 4,000/ cu mm, or > 10 % immature 
band forms 
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4.2.2 SEPSIS 
Sepsis is a deleterious dysregulated inflammatory response of the body to an infection which 
results in severe sepsis, septic shock with or without multi organ dysfunction (6). 
The definition of sepsis has been reconsidered since 1991, with the latest definition from the 
Society of Critical Care Medicine and European Society of Intensive Care Medicine in 2012 
(6). 
The diagnostic criteria for sepsis included: 
Infection, documented or suspected, and some of the following: 
General variables 
1. Temperature; fever >38.3 ºC or hypothermia <36 ºC 
2. Heart rate >90 beats/min or more than two standard deviations above the normal 
value for age 
3. Tachypnea, respiratory rate >20 breaths/min 
4. Altered mental status 
5. Significant edema or positive fluid balance (>20 mL/kg over 24 hours) 
6. Hyperglycaemia (plasma glucose >140 mg/dL or 7.7 mmol/L) in the absence of 
diabetes 
Inflammatory variables 
1. Leucocytosis (WBC count >12,000 microL–1) or leukopenia (WBC count <4000 
microL
–1
) 
2. Normal WBC count with greater than 10 percent immature forms 
3. Plasma C-reactive protein more than two standard deviations above the normal value 
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4. Plasma procalcitonin more than two standard deviations above the normal value 
Hemodynamic variables 
Arterial hypotension (systolic blood pressure SBP <90 mmHg, MAP <70 mmHg, or an SBP 
decrease >40 mmHg in adults or less than two standard deviations below normal for age) 
Organ dysfunction variables 
1. Arterial hypoxemia (arterial oxygen tension [PaO2]/fraction of inspired oxygen 
[FiO2] <300) 
2. Acute oliguria (urine output <0.5 mL/kg/hr for at least two hours despite adequate 
fluid resuscitation) 
3. Creatinine increase >0.5 mg/dL or 44.2 micromol/L 
4. Coagulation abnormalities (international normalized ratio [INR] >1.5 or activated 
partial thromboplastin time [aPTT] >60 seconds) 
5. Ileus (absent bowel sounds) 
6. Thrombocytopenia (platelet count <100,000 microL–1) 
7. Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 micromol/L) 
Tissue perfusion variables 
1. Hyperlactatemia (>1 mmol/L) 
2. Decreased capillary refill or mottling  (5, 6) 
4.2.3 SEPTIC SHOCK 
Septic shock is sepsis induced with hypotension despite adequate fluid resuscitation along 
with the presence of perfusion abnormalities that may include, but are not limited to lactic 
acidosis, oliguria, or an acute alteration in mental status (5, 6). 
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4.2.4 SEVERE SEPSIS 
Sepsis associated with organ dysfunction, hypo perfusion or hypotension. Hypo perfusion 
and perfusion abnormalities may include lactic acidosis, oliguria, or an acute alteration in 
mental status (5, 6). 
4.2.5 MULTI ORGAN DYSFUNCTION 
Multi organ dysfunction (MODS): presence of altered organ functions in an acutely ill 
patient such that homeostasis cannot be maintained without intervention (5). 
4.3 SEVERE COMMUNITY ACQUIRED INFECTIONS REQUIRING INTENSIVE 
CARE 
Data on clinical outcomes of severe community acquired infections from a study done by 
Hounsom et al on 681 patients admitted to UK NHS international showed that the 7 and 30 
day mortality rates were 18.2 % and 25 % respectively. This study however included all 
patients with community acquired bacteremia irrespective of the severity. The 30 day 
mortality in the critical care unit was 29.2%. The spectrum of infection in this cohort was 
bacteremic illnesses with the commonest site of infection being urinary tract infection 
followed by biliary tract infection. The most common organism that was isolated was 
Escherichia coli in 34.7% of the patients, followed by Staphylococcus aureus in 12.2% and 
Streptococcus pneumonia in 5.8 %. Among those with E.coli bacteremia, 8.8% was 
accounted for by extended spectrum beta lactamase producers (7). 
The risk factors for mortality identified in this study and in another study by Ispahani et al 
included age, inadequate response to treatment, shock, leukopenia, polymicrobial 
bacteremia, pre-existing co morbidities and unidentified site infections (7, 8, 9).  
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Eykyn et al in another study in UK showed a similar microbiological spectrum in 
bacteremic illnesses. They also showed that E.coli bacteremia was common in those with 
diabetes, while Streptococcus pneumoniae was more common among alcoholics (10). 
Even though the data is sparse, Reddy et al in the meta analysis on community acquired 
blood stream infections in Africa, looked at 22 studies on community acquired infections in 
both adults and children (11). 
The prevalence of blood stream infections in the adult population was 13.5 % of which non-
typhoidal Salmonella bacteremia was the prevalent isolate at 58.4 % followed by 
S.pneumoniae at 18.3%, S. aureus at 9.5 % and E. coli at 7.3%. The in- hospital case fatality 
rate was 18.1%. Through this meta analysis it is evident that though Africa is endemic for 
malaria, bacteremic febrile illnesses are common as well (11, 12). However none of these 
studies looked at the predictors of mortality. 
Irrespective of the type of infection or the source of infection, the single most significant 
modifiable risk factor identified was early administration of appropriate antimicrobial agent 
(7, 8, 9). 
In a prospective, multicentre, observational study, done by Valles et al in 30 ICUs in Spain, 
they showed that inappropriate and inadequate antimicrobial therapy was associated with 
poor prognosis and increase in mortality (13). 
So in a patient with septic shock where the source of the infection or the infectious 
syndrome is not known, it is prudent to initiate on broad spectrum antibiotics. However one 
needs to be aware of the epidemiology of the infection in ones area to be able to decide on 
the most appropriate antibiotics therapy (13). 
Page | 24  
 
Also it is essential that clinicians are equipped to recognize the various infectious 
syndromes, are aware of the epidemiology and clinical spectrum of these infectious 
syndromes and initiate appropriate therapy in order to reduce the case fatality rate, more so 
in resource constrained settings such as in Africa and even in India. 
It is also evident that there is lack of data from India and even from other developing nations 
such as Africa on clinical spectrum and outcomes of severe community acquired infections 
that require intensive care.  
4.4 COMMUNITY ACQUIRED PNEUMONIA 
According to the British Thoracic Society community acquired pneumonia (CAP) in a 
patient admitted to the hospital is defined as: 
1. Symptoms of an acute lower respiratory tract illness (cough with purulent sputum 
production and at least one of  the lower respiratory tract symptoms such as pleuritic chest 
pain, dyspnea and tachypnea) 
2. New focal chest signs on  examination 
3. At least one systemic feature (either a symptom  complex o sweating, shivers, aches 
and pains and/or temperature of 38°C or more )  
4. No other explanation for the illness, which is treated as CAP with antibiotics. 
5. New radiographic shadowing for which there is no other explanation (14). 
CAP remains a common infection worldwide including India. The exact incidence of the 
disease in India is not known. Annually around 4 million cases of CAP occur with over 20 
% of the patients require hospital admission (15, 16). 
Mortality is higher in those with severe infection requiring ICU care. 
Page | 25  
 
The bacteriological profile varies in each country and in India there are few studies looking 
at the etiological agents implicated. 
In a study in 2 tertiary hospitals in Delhi, the common organisms implicated as causative 
agents in CAP was S. pneumoniae (35.3%) S.aureus (23.5%), Klebsiella pneumoniae 
(20.5%) and Haemophilus influenza (8.8%) (17).   
On the contrary in a study by Aroma et al from Christian Medical College Ludhiana, the 
most common organism isolated from the blood in patients with CAP was Pseudomonas 
aeroginosa (18). 
But the most common organism implicated in CAP is S. pneumoniae, even in India (17, 19). 
4.5 SCRUB TYPHUS 
Scrub typhus is a rickettsial infection which is endemic to south and sout eastern Asia, 
Asian Pacific Rim and the northern Australia (20). 
Scrub typhus is a mite-borne infection which is caused by an obligate intracellular gram 
negative coccobacillus Orinetia tsutsugamushi which is classifies in the Rickettsia genus. 
The disease is transmtted to man by the bite of the larval stage of trombiculid mite of 
Leptotrombidium genus (20, 21). 
The true burden of the disease from Indian sub-continent is unavailable due to lack of 
community based data and often the disease is under diagnosed or mis diagnosed. However 
in the recent years there have been reports of the remergence of this infection from various 
states in India namely Jammu and Kashmir, Himachal Pradesh, Uttaranchal, Rajasthan, 
Assam, West Bengal, Maharashtra, Tamil Nadu and Kerala (2, 21-25). 
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 In a study conducted in Christian Medical College Vellore by Anugrah et al, the proportion 
of cases presenting with an acute febrile illness who had scrub typhus was 47.5 %.( 2). In 
certain regions scrub typhus accounts for up to 50% of all cases of acute undifferentiated 
febrile illnesses (26, 27). 
The commonest presenting symptom is short duration fever, and is often associated with 
dyspnea, cough, nausea, vomiting, myalgia and headache (2, 21, 28, 29). The most 
characteristic clinical finding seen in patients with scrub typhus is the presence of an eschar 
which is seen at the site of inoculation (2, 21). 
The presence of an eschar is highly variable ranging between 10-92 %. In 2 studies from a 
tertiary hospital in South India the presence of eschar was seen in approximately 55% of 
patients (21, 30, 31). 
The commonest site included chest and abdomen (42.3%) among females and the axilla, 
groin and genitalia (55.8%) in males (31). 
 
Fig 2.Sites of eschar (adapted from Ref 31) 
The infection may be mild wherein the patients usually respond well to oral doxycycline.  
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However a small percentage of patient’s may present with severe infection leading on to 
multi organ dysfunction and require intensive care. Patients with severe form of scrub 
typhus present with various organ dysfunctions namely acute kidney injury, meningo 
encephalitis, aseptic meningitis, myocarditis, septic shock, transaminitis, and acute 
respiratory distress syndrome (2, 21). 
Mortality due to scrub typhus has been on down ward trend despite the varying mortality 
rates between various studies. The average case fatality rate reported by Varghese et al from 
a tertiary hospital in South India in 2014 was approximately 9% which was much lower than 
the 14% case fatality rate  reported from the same institution in 2006 (21,32). 
 Even across India, there has been a declining trend in mortality from 14.6% in 2007 to 
7.6% in 2010. (21). 
This probably is a reflection of awareness among medical practitioners, early diagnosis and 
initiation of therapy. 
The predictors of mortality included shock necessitating use of inotropic agents, renal 
dysfunction and CNS dysfunction. The commonest multi organ dysfunction seen was acute 
respiratory distress syndrome, as shown by Varghese et al, with an incidence of 34 % and 
more than half these patients required ventilatory support (21). 
However the incidence of renal dysfunction varied across studies with an incidence of 18% 
as reported by Varghese et al to 23.2 % as reported by Attur et al. Nevertheless acute renal 
failure was one among the independent predictors of mortality (21, 33). 
Patients with scrub typhus may have thrombocytopenia, transaminitis, leukopenia or 
leucocytosis and deranged renal functions. The severity of the laboratory abnormalities 
differ and tend to be more severe in those with multi organ dysfunction (2, 21, 32, 33). 
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The diagnosis of scrub typhus may be easier in the right clinical setting. Serologic test of 
choice available is IgM ELISA or immunofluorescence assay which is the gold standard 
(34, 35). So the diagnosis of scrub typhus can be made when either one of the following are 
present 
 Eschar  with  Scrub IgM ELISA positive  
 OR Scrub IgM ELISA positive WITH  defervesence within 4 hours of initiation of 
doxycycline OR  
 Scrub IgM ELISA seroconversion on convalescent sera 
  OR Scrub IgM ELISA with other serologies negative (2, 34, 35). 
The varying clinical presentations, and similarities with other undifferentiated illnesses such 
as malaria, dengue fever, severe gram negative bacterial infections, CNS infections, 
sometimes can make the diagnosis difficult.  
4.6 MALARIA 
Malaria is a parasitic infection which is caused by Plasmodium species, which is transmitted 
via the bites of infected mosquitoes namely.  The Plasmodium species implicated are 
Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, and. Among these the 
species that are known to cause severe infections is the Plasmodium falciparum (36, 37). 
Infections caused by P.falciparum and P.vivax are of great public health concern in the 
tropical countries. Malaria is transmitted by female Anopheles mosquito. Of the 400 species 
identified, 30 are vectors of significance in transmission. Two of the widely used 
antimalarials are derived from plant sources – artemisinin derivative (Artemisia annua), 
Quinine (Cinchona) are currently in use in areas endemic for malaria transmission (38). 
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Active transmission is documented in 104 countries and are presently endemic for malaria 
as of WHO global malaria report 2013 (39). 
In a the acute febrile illness study conducted by Anugrah et in Christian Medical College 
Vellore, malaria accounted for 17.1 % (68 cases) of all cases of acute febrile illness. Of 
these P.falciparum infection was seen in 39 cases, P.vivax in 6 cases and mixed infection 
was accounted for by 6 cases and death occurred in 7.4 5 % of all cases (2). 
95% population in India live in malaria endemic areas and 80% of malaria reported in the 
country is confined to areas which are hilly terrains, inaccessible to medical care (40). 
50 % of reported cases are caused by P.falciparum species and 50% by P.vivax species. 
North and north eastern India are endemic for P.falciparum infection. The common 
anopheles species found include An. fluviatilis, stephensi, dirus, minimus, annularis and 
culicifacies. 
Public sector based interventions by the NMEP have contributed significantly to the decline 
in incidence of malaria cases. Presently malaria diagnostic tests as well as ACT has been 
administered free of cost in the public sector. Extensive preventive measures are in place 
which includes larval control as well as the larval control measures (40). 
Contrary to the national and WHO data of decline in the number of cases has been on a 
decline from the year 2002, a study published in The Lancet in 2010 by Dhingra et al 
showed that the malarial deaths are grossly underestimated and they had reported 1, 20,000 
deaths/year in India, as compared to national statistics which reported the number to be 1230 
deaths. The mortality occurred in geographical areas which are highly endemic for 
P.falciparum infections (41, 42). 
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Malaria is diagnosed in a patient with patient who presents with acute febrile illness with 
identification of the parasite (Plasmodium vivax, Plasmodium falciparum or mixed 
infection) on blood smears (2).  
Artesunate and sulphadoxine- pyrimethamine combination is currently recommended first 
line treatment. Most patients with uncomplicated malaria respond to anti-malarial therapy 
and do not require intensive care (43) 
However those with complicated malaria usually caused by P. falciparum tend to have multi 
organ dysfunction. The organ involvement can be metabolic acidosis, circulatory 
collapse/shock, acute respiratory distress syndrome/pulmonary edema, hemoglobinuria, 
anaemia, thrombocytopenia, acute kidney injury, acute liver failure/hepatic encephalopathy, 
hypoglycaemia, and altered sensorium/seizures/cerebral malaria. Severe malaria is managed 
by parenteral anti-malarial mainly quinine or artemisinin based combination therapy (36, 
37). 
Most cases of P.vivax malaria cause benign infections. However in a recent retrospective 
analysis in a tertiary care centre in Uttar Pradesh India, 62 patients with P.vivax infections 
were identified to cause severe malaria. In this study mixed infections and falciparum 
malaria was excluded. The reported complications included renal dysfunction (21 %), 
cerebral malaria (10%), hepatic dysfunction (29%), severe anemia (25.8 %), 
thrombocytopenia (56.5%), acute respiratory distress syndrome (9.7%), hypoglycaemia (4.8 
%) and shock (16.1%) (44). 
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4.7 URINARY TRACT INFECTION/PYELONEPHRITIS 
Urinary tract infections are common infection in India. However there are no large studies 
which have looked at the overall prevalence and epidemiology of the organisms in the 
country. In two clinico-microbiological profile studies on urinary tract infection done in 
India by Akram et al in Aligarh in 2007 and Eshwarappa et al in 2008,  E.coli  was the 
commonest organism with 61% and 66.9% respectively with ESBL rates of 42.2% and 42% 
respectively across all organisms (45,46). 
 In the study by Akram et al the other organisms found to cause UTI were Klebsiella spp - 
22% and Pseudomonas. spp 34.4 % of ESBL producing organisms were E.coli and 27.3% in 
Klebsiella spp (46).  A similar clinical microbiological profile was found in various studies 
conducted all across India (47-50). 
Females are most commonly affected, with elderly age groups and diabetes mellitus being 
the two most common risk factors. (51,52). 
Patients with diabetes also tend to have a complicated clinical course wherein they develop 
complications such as emphysematous pyelonephritis, papillary necrosis and worsening of 
renal failure with residual damage in some patients (51). 
Even in the elderly the clinical presentation is complicated by the masking of the typical 
symptoms. Often they present with just an acute confusional state, thus the clinician ought 
to be astute to make the correct diagnosis (53). 
4.8 ACUTE CENTRAL NERVOUS SYSTEM INFECTION 
Acute central nervous system (CNS) infections form a spectrum of illnesses which include 
meningitis, encephalitis or meningoencephalitis. Meningitis is defined by presence of fever, 
headache, and meningeal irritation. Encephalitis is defined by the presence of inflammatory 
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process of the brain in association with clinical evidence of neurological dysfunction. In 
other words a patient with fever, headache, altered mental status, focal neurological signs 
Meningoencephalitis is defined as a condition when the patient has features of meningismus 
and features of encephalitis. The diagnosis of acute CNS infection is based on the clinical 
features mentioned above and positive cerebrospinal fluid analysis. 
Acute bacterial meningitis is a major cause of morbidity and mortality if untreated. The 
mortality in India and other developing countries due to acute bacterial meningitis ranges 
from 16-32 % (54). 
In a 10 year retrospective study of all cases of community acquired bacterial meningitis at 
NIMHANS, Bangalore (January 1996 to December 2005), the etiological agent was 
identified in 284 (73.8%) of the total of 385 cases. The commonest organism implicated was 
S. pneumoniae which accounted for 61.8% of all the 385 cases. The other pathogens 
included H.influenza (1.8%) and Neisseria meningitidis (1%), gram negative bacilli (4.9%), 
Streptococcus spp. (2.3%) and S. aureus (1.8%). These organisms were identified using 
culture or gram stain or latex agglutination method (LAT) (55). 
Contrary to the data of S.pneumoniae as the commonest agent implicated in acute bacterial 
meningitis, as obtained in most studies in India (54 - 57), Sonavane et al in a retrospective 
analysis of 7759 clinically suspected cases of meningitis, admitted in a tertiary Hospital in 
Bombay, from February 2005-February 2008, isolated P. aeruginosa (23.25%) as the most 
common pathogen. The other organisms included Klebsiella pneumoniae (20.93%), 
Acinetobacter spp (20.93%), S.pneumoniae (18.60%), N.meningitidis (4.65%), 
Streptococcus pyogenes (4.65%), Enterococcus spp. (2.23%) and other Streptococcus spp. 
(2.23 %.) (58). 
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Vibha et al analysed both retrospectively and prospectively all cases of clinically suspected 
community acquired bacterial meningitis admitted at AIIMS, Delhi, and found that the 
following factors namely patients from rural area, presentation after 24 hours of onset of 
illness, peripheral total leucocyte count of < 15000, CSF neutrophils of < 75%, low 
Glasgow coma scale at admission, and high creatinine levels were independent factors of 
mortality (59). 
According to studies from international literature, acute bacterial meningitis is associated 
with acute systemic and neurological complications. In a prospective clinical study in a 
Germany, done by Pfister et al on 86 adult patients with acute bacterial meningitis, the 
major neurological complications included brain swelling in 14%, hydrocephalus in 11.6% 
and intracerebral haemorrhage in 2.3 % of cases. Seven patients had cerebral herniation. The 
major systemic complications seen included septic shock (11.6%), acute respiratory distress 
syndrome (3.5%) and disseminated intravascular coagulation (8.1%) (60). 
There is however no Indian studies which have looked at the spectrum of acute neurological 
and systemic complications in acute bacterial meningitis in adult population. 
Acute encephalitis syndrome constitutes a large proportion of cases with acute CNS 
infection. In India seasonal outbreaks of acute encephalitis have been reported since 1973. 
The common agents implicated in acute encephalitis include Herpes simplex virus type 1, 
West Nile virus, Chandipura virus, Japanese encephalitis B virus, enteroviruses (61). 
In a record-based study which looked at cases of acute encephalitis syndrome in India and 
Nepal between 1978 and 2011, 125,030 cases were identified from India with mean 
Incidence rate of 0.42 for India (62). 
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Joshi et al looked at the clinical spectrum of acute encephalitis syndrome in rural central 
India, where 183 cases were identified between January 2007 and October 2007. Amongst 
these 152 cases were identified as possible viral encephalitis, however the etiology of the 
same was confirmed in only 31 cases. The etiological organisms identified using PCR 
analysis on the CSF were enterovirus (11.2%), flavivirus (5.2%), Varicella zoster (1.9%), 
herpes virus (0.6 %)%). The mortality rate was about 36 %. (63). 
In a review article written by Rajinish et al published in 2012 looked at various studies done 
in India on acute viral encephalitis. In the article most of the studies identified Japanese 
encephalitis virus as the etiological agent in the years between 1975 and 1999. On the other 
hand newer viruses such as Chandipura virus and enetroviruses were identified as causative 
agents after 2000 (64). 
 In eastern India, Rathore et al through a hospital-based case enrolment study between April 
2011 and July 2012 identified 91 cases of serology proven viral encephalitis from among 
526 cases of acute encephalitis syndrome. The most common agent identified was Herpes 
simplex virus (16.1%). The other agents included measles virus (2.6%), Japanese 
encephalitis virus (1·5%), dengue virus (0·57%), varicella zoster virus (0·38%) and 
enteroviruses (0·19%) (65). 
4.9 ENTERIC FEVER 
Enteric fever is a systemic febrile illness caused gram negative bacteria namely Salmonella 
enterica serotype Typhi, and Salmonella enterica serotype paratyphi A, B or C. Enteric 
fever comprises both typhi and paratyphoid illnesses (66).  
Crump et al looked at 22 population-based studies to estimate the global burden of the 
typhoid fever and as per data obtained the highest burden was seen in South central Asia and 
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South east Asia as evidenced by high incidence of > 100/100,000 cases/year. The estimated 
number of deaths globally due to typhoid disease was 216.510 and deaths due to 
paratyphoid caused 5,412,744 illnesses. This data high lights the burden of the disease 
globally (67). 
Epidemiological data has shown that this is a disease of the developing countries (67, 68).  
Looking at the burden of the disease in India, there have been 6 landmark population based 
studies which has reported varying incidence rates (69-74). 
Of these 3 studies were vaccine trials done by Chuttani et al between 198- 1978, in the Delhi 
urban slums. The studies predominantly looked at paediatric population and adolescent age 
groups. The incidence reported were 9.6/1000 person years in 1971, 7.6/1000 person years 
in 1973 and 7.4/1000 person years in 1977 (69-71). 
On the other hand similar study conducted in the urban slums of Kolkata by Ochelai et 
showed a much lower incidence (72, 73). 
From these data it is evident that enteric fever is the most common bacetremic illness in 
south Asia, with special reference to the Indian sub-continent. Enteric fever accounted for 
8% of all the cases of acute febrile illness studied by Anugrah et al at Christian Medical 
College Vellore (2). 
 The burden of this disease is enormous and to complicate matters, various studies from the 
Indian sub-continent have documented emerging resistance to antibiotics. (68) 
Nagishetty et al analysed isolates from 1250 samples which included 1200 blood culture 
samples and 50 environmental samples for resistance pattern and showed an alarming 
pattern of resistance as evidenced by 31.57% of resistance against Nalidixic acid and 
29.47% of resistance to ampicillin. S. typhi was isolated from 11 environmental samples and 
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84 blood samples (75).  A similar pattern of resistance has been seen in various studies done 
at various centres in the country. In a 3 year study done in a tertiary hospital in Chandigarh 
in North India by Gupta et al 302 cases of Salmonella spp was isolated from 24390 blood 
culture samples over a 3 year period, and of these 257 cases were caused by S. typhi and the 
remaining 45 were caused by S. paratyphi. There was 100 % resistance recorded against 
Nalidixic acid (76). 
Rupali et al in 2004, from Christian Medical College, Vellore in Tamil Nadu analysed for 
treatment failure in 109 hospitalized patients with blood culture proven Sallmonella typhi 
infection. All these patients were treated with ciprofloxacin. Clinical failure as defined by 
fever persisting for more than 6 days was documented in 25 of 46 cases who were evaluated, 
while microbiological failure positive blood culture even after 6 days of therapy with 
ciprofloxacin was seen in 8 (17.4 %). All the 8 strains of S.typhi was susceptible to 
ciprofloxacin with minimum inhibitory concentration <1 microgram/ml. However when 
compared to the pattern of MIC seen in the S. typhi strains isolated in 1995 there was 15 fold 
rise in minimum inhibitory concentration (77). 
However the major limitation in most of the studies was that the clinical spectrum of 
involvement, outcome or the implications on mortality in relation to the alarming pattern of 
resistance of resistance documented was not analysed (78).  
One landmark study done in a tertiary care center in New Delhi, north India by Kadhivaran 
et al over a period of 2 years, looked at the clinical outcomes in patients with Nalidixic acid 
resistant strains. In this study 60 cases of culture proven S.typhi was analysed. All the 60 
isolates were susceptible to ciprofloxacin as per the MIC break points. However clinical 
failure was documented in 11 patients who were treated with fluoroquinolones and all these 
were NARST isolates. On the other hand 47 of the 60 cases that is 785 of the isolates 
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showed resistant pattern against Nalidixic acid. Though not statistically significant, the 
duration of fever at presentation and the total duration of illness were longer in those with 
NARST isolates. However other major complications due to the illness was not analysed in 
this study (79). 
Considering the enormous burden of the disease in India, a deeper and evidence based 
understanding of whether the alarming pattern of resistance has any implications on the 
clinical outcomes and mortality is the need of the hour.  
4.10 DENGUE FEVER 
Dengue infection is a mosquito borne viral disease, caused by 4 closely related but 
serologically different dengue viruses. These viruses are called DENV-1, DENV-2, DENV-
3 and DENV- 4 and belong to the genus Flaviviridae. As mentioned it is an arboviral 
disease transmitted mainly by the bite of Aedes mosquito (80, 81). 
Over 2.5 billion of the world’s population live in areas at risk for dengue fever. It is 
estimated that approximately 390 million dengue infections occur every year (81-83). 
 Moreover in the recent few decades the incidence of this infection has increased 
tremendously making dengue infection a serious public health disease, more so in the 
tropical countries (84-86). 
In India the first epidemic of Dengue was recorded in Chennai in 1780. However the first 
virologically proven epidemic was in 1963-64 in Calcutta and the Eastern Coast of India 
(87-89). 
This epidemic in 1963-64 spread gradually to involve the whole country. Initially it was 
confined to the northern parts of the country affecting people in Deli in 1967 (90), followed 
by Kanpur in 1968 (91, 92). Subsequently the southern part of the country was also affected 
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(93, 94). The virus spread in an endemic/ hyper endemic fashion and all 4 serotypes were 
implicated.  
In 2010 there was an epidemic in India with nearly 28,066 serologically confirmed cases. In 
all the outbreaks various serotypes were implicated. Though infection with one serotype 
offers lifelong immunity, protection against other serotypes is transient. This change in the 
serotype with each outbreak and the transient cross protection between serotypes are major 
factors responsible for the large number of cases every year. (87, 95-97). 
In human beings dengue virus can cause a spectrum of illness ranging from a self-limiting 
mild febrile illness to severe haemorrhagic illness. (102,103) 
Dengue is classically characterized by short duration febrile illness, with non-specific signs 
and symptoms such as headache, retro-orbital pain, conjunctival congestion nausea, 
vomiting, joint pains, myalgia, and rash. The rash in dengue is variable ranging from facial 
flushing to scarlatiniform to Maculopapular eruptions typically involving the trunk initially 
followed by the face and extremities (102). 
The term “break-bone” fever has been used in dengue as these patients have severe joint 
pains and myalgia (104). 
On the contrary dengue haemorrhagic fever and dengue shock syndrome is more fatal. 
Patients can present with haemorrhagic manifestations of varying severity. They may have 
gum bleeding, epistaxis, GI bleeding hematuria or major intra-abdominal bleeding. Some 
may exhibit signs of circulatory failure as well. With supportive therapy, and fluid 
resuscitation with or without the support of blood products, these patients usually recover 
(103). 
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The common laboratory abnormalities seen are leukopenia, thrombocytopenia, 
hemoconcentration, elevated transaminases (102). 
Considering the non-specific clinical presentation and lab abnormalities confirmation of 
dengue infection is accomplished using serology. There are 5 basic serologic tests available, 
namely hemagglutination-inhibition, complement fixation, immunoglobulin M capture 
enzyme-linked immunosorbent assay, neutralization test and indirect immunoglobulin G 
ELISA (105,106). 
Hemagglutination-inhibition is one of most commonly used tests. It is a sensitive test that is 
easy to perform. The antibody begins to appear by day 5 of the illness. Though not a specific 
test, it is useful for seroepidemiologic studies as the antibodies persist for longer duration. 
On the other hand neutralization test is both a sensitive and specific test (106). 
4.11 RATIONALE AND JUSTIFICATION OF THIS STUDY 
Normally infections are categorised on their anatomical site of involvement, the clinical 
syndrome and their etiology. With development of ICU care, there has been the physical 
segregation and specific protocols of management in patients with serious infections 
requiring high dependency and critical care. This is reflected in management trends such as 
surviving sepsis campaign bundle. In this group of patients with community acquired 
infections requiring ICU and HDU care, the clinical syndromes may not be differentiated 
and diagnosis may not be certain at admission. This is also the group of infections 
associated with highest mortality. Clinical decision making in relation to establishing 
diagnosis, early initiation of specific antimicrobial therapy and organ system support is of 
vital importance in determining outcome. The goal of this study is describe the clinical 
profile and outcomes of these seriously sick community acquired infections requiring ICU 
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and HDU care. This understanding may contribute to better clinical management of this 
group of patients. 
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5. METHODS 
5.1 SAMPLE AND SETTING 
 
The study was conducted between January 2013 and October 2014 at CMC, Vellore.  
Patients presenting with acute febrile illness, requiring admission into medical intensive care 
units and medical high dependency unit, fulfilling the inclusion criteria and willing to 
participate in the study were included into the study. There were two arms to the study- 
retrospective and prospective arms. The study and the research procedures were fully 
explained to the participants, participating in the prospective arm and those who gave 
written consent were allowed to participate in the study. The consent was obtained in the 
regional language that the patient/relative was conversant (Annexure 1) 
RETROSPECTIVE ARM OF THE STUDY 
All patients under the department of General Medicine who were admitted in Medical 
ICU/HDU after January 2013 who fulfilled the inclusion criteria were included in the study. 
As this is a retrospective arm of the study, patient information sheet and informed consent 
were not obtained. The primary investigator collected the hospital numbers of these patients 
after going through the discharge summaries. 
The required details were entered in the data extraction form after going through the 
discharge summaries and IP records. 
 
 
 
 
 
The principal investigator went through the discharge summaries of all patients admitted 
under the department of general medicine from January 2013 till January 2014. 
Those patients fulfilling the inclusion criteria were included in the retrospective arm of the 
study. 
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PROSPECTIVE ARM OF THE STUDY 
 
All patients admitted in ICU/HDU who fulfilled the inclusion criteria were enrolled in the 
study after obtaining an informed written consent. The primary investigator visited the 
ICU/HDU on a daily basis to identify the cases. After the informed consent is obtained the 
data was filled using a primary admission sheet. The investigator followed up the patient on 
a daily basis till discharge. 
The patient was assessed on a daily basis for development of any new onset organ 
dysfunction or any ensuing complications unrelated to the disease. 
The in patient records were reviewed at discharge for completion of the data. Cost of care 
with reference to antibiotics and total cost of ICU/HDU care and hospital stay was entered 
after discharge or death. 
 
 
 
 
 
 
 
 
Details were entered in the data extraction form after going through the discharge 
summaries and, OPD charts and  the IP records. 
 
After obtaining informed consent, patients fulfilling the inclusion criteria were 
recruited after they are admitted into MICU/MHDU 
The patients were recruited by the primary investigator. 
Data was entered in the data sheet or data extraction form. 
Relevant investigations will be entered through information obtained from clinical work 
station. 
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5.2 STUDY DESIGN 
 
The study design is a retrospective and prospective observational study of patients with 
community acquired infections admitted by the Department of General Medicine into 
Medical Intensive Care Unit and Medical Hugh Dependancy Unit in Christian Medical 
College Vellore, Tamil Nadu, India.  
 
5.3 SAMPLE SIZE 
We went through the records of all patients admitted into medical intensive care 
unit/medical high dependency unit between January 2013 and August 20013. There 589 
admissions in MHDU/MICU. Of the 589, 87 patients had severe community acquired 
infections. Therefore the prevalence of severe community acquired infection was around 
14.77%. 
The prevalence of severe community acquired infection was around 14.77 %, 
 The primary objective is to look at the spectrum of severe community acquired infections 
and the outcome of this group of patients. 
Patients were followed up on a daily basis while in MICU/MHDU, and till discharge or 
death. 
Details of existing multi organ dysfunction, new onset organ dysfunction and complications 
unrelated to the primary illness were entered 
OPD chart, emergency room notes, in patient records, clinical work station were used for 
completion of records 
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 Assuming the expected prevalence of severe community acquired infections in medical 
intensive care unit/ medical high dependency unit to be 15 % with 95% confidence interval 
and precision of 3%, the sample size required is 566.  
5.4 PARTICIPANTS 
The participants in this study fulfilled the following inclusion criteria: 
Inclusion criteria 
I. Age more than 16 years 
II. Patients with SIRS and with features of community acquired infection (<3 weeks duration at 
presentation). These include the diagnoses such as community acquired pneumonia. Urinary 
tract infections, skin and soft tissue infections, meningitis /acute CNS infections, 
undifferentiated febrile illnesses, rickettsial infections, malaria, viral fever, enteric fever and 
unidentified source. 
Exclusion criteria 
I. Admitted to another hospital for more than 1 week 
II. Suspected  nosocomial infection at admission 
 
5.5 MEASUREMENTS – DATA COLLECTION 
 
The data collection was done in data abstraction forms (Annexure 2) by the principal 
investigator of the study once the patients are admitted into medical intensive care unit or 
medical high dependency unit and they were followed up until discharge. The following 
details were recorded specifically: 
1) Demographics – Age, sex, occupation. 
2) Symptoms and duration of symptoms 
3) Clinical assessment details – vital signs, systemic examination 
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4) Presence and duration of complications 
5) Laboratory parameters including haematological, biochemical tests, serology and 
microbiological tests. 
5.5.1 SVERITY OF INFECTION 
INFECTION: A microbial phenomenon characterized by an inflammatory response to the 
presence of micro-organisms or the invasion of normally sterile host tissue by those 
organisms. 
BACTEREMIA: presence of viable bacteria in the blood in the absence of contamination. 
SEVERITY OF THE INFECTION 
a) SIRS- 
 Temperature: >38 deg C or < 36 deg C 
 Heart rate : > 90 beats per minute  
 Respiratory rate: >20 breaths per minute or PaCO2 < 32 mmHg 
 White blood cell count: > 12,000/ cu mm or < 4,000/ cu mm, or > 10 % immature band 
forms 
b) SEPSIS: systemic response to infection manifested by two or more of the following  
conditions as a result of infection: 
 Temperature: >38 deg C or < 36 deg C. 
 Heart rate : > 90 beats per minute  
 Respiratory rate: >20 breaths per minute or PaCO2 < 32 mmHg 
 White blood cell count: > 12,000/ cu mm or < 4,000/ cu mm, or > 10 %      immature 
band forms (elaborated in the literature review text). 
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c) SEPTIC SHOCK: septic shock is sepsis induced with hypotension despite adequate fluid 
resuscitation along with the presence of perfusion abnormalities that may include, but are 
not limited to lactic acidosis, oliguria, or an acute alteration in mental status. 
d) SEVERE SEPSIS: Sepsis associated with organ dysfunction, hypo perfusion or 
hypotension. Hypo perfusion and perfusion abnormalities may include, lactic acidosis, 
oliguria, or an acute alteration in mental status 
e) MODS (multi organ dysfunction): presence of altered organ functions in an acutely ill 
patient such that homeostasis cannot be maintained without intervention. 
 5.5.2 DEFINITION OF INDVIDUAL INFECTIONS/ SYNDROMES 
Pneumonia:  
Pneumonia is defined as inflammation and consolidation of the lung tissue. 
Acute undifferentiated febrile illness 
SCRUB TYPHUS- either one of the following  
 Eschar  with  Scrub IgM ELISA positive  
 OR Scrub IgM ELISA positive WITH  defervesence within 4 hours of initiation of 
doxycycline OR  
 Scrub IgM ELISA seroconversion on convalescent sera 
  OR Scrub IgM ELISA with other serologies negative 
Malaria: 
Positive malaria pararsite- (trophozoites – Falciparum, Vivax or mixed) visualized on thin 
blood 
smears. 
Enteric fever 
Enteric fever – Blood culture positive for Salmonella typhi or S. paratyphi OR Typhidot 
(IgM) positive plus  other serologies negative OR fourfold rise in titre on the WIDAL 
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Dengue fever 
High fever with any tow of the following symptoms- severe headache, pain behind the eyes, 
muscle and joints, nausea, vomiting swollen glands or rash 
Warning signs- with a decrease in temperature (below 38°C/ 100°F) and include: severe 
abdominal pain, persistent vomiting, rapid breathing, bleeding gums, fatigue, restlessness, 
blood in vomit. 
Dengue fever – Dengue IgM positive or other serologies negative OR seroconversion on 
convalescent sera. 
 Dengue haemorrhagic fever (DHF) – Above criteria along with thrombocytopenia with 
haemorrhage. 
 Dengue shock syndrome (DSS) – Shock (BP, 90mmHg) and other features of DHF. 
 
Urinary tract infections: 
Patients who present with fever with chills and  lower urinary tract symptoms such as 
dysuria, frequency, urgency, supra pubic pain/ tenderness associated with any of the 
following systemic symptoms, such as nausea, vomiting, flank pain, delirium.  
Presence of haematuria or cloudy urine. 
Presence of pyuria and isolation of a typical organism in the urine and/or blood, that causes 
urinary tract infection. 
. 
Acute CNS infection: 
Meningitis: Fever with headache, meningismus and altered mental status 
Encephalitis: Fever with headache, altered mental status, focal neurological signs. 
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Table 1. CSF analysis in acute CNS infections 
CAUSE WBC PRIMARY 
CELL TYPE 
GLUCOSE PROTEIN 
Bacterial >500 
(usually > 
1000).   
Early: May 
be < 100. 
POLYMORPH <45 mg/dL > 250 mg/dL 
Viral < 100 
cells/µL. 
Early: 
neutrophils.  
Late: 
lymphocytes 
Normal   
(> 45 
mg/Dl). 
<100 mg/dL  
 
 
 
5.5.3 DISEASE SEVERITY SCALE 
 
APACHE II SCORE 
Total Acute Physiology Score (APS) Sum of the individual 12 points = A 
Total APACHE 2 score = Sum of A (APS) +B (age) + C (chronic health points) 
C= Chronic health points  
 Elective post op      +2 pts 
 Non operative or emergency post op +5 pts  
 If any of the below is yes give +5 pts:      
1) Cirrhosis with portal hypertension or hepatic encephalopathy  
2) Class IV angina at rest  
3) Chronic hypoxemia, hypercapnia or polycythaemia 
4) Chronic peritoneal or haemodialysis 
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                    5) Immunocompromised host  
Table 2. APACHE II SCORE 
 
 
HIGH ABNORMAL LOW ABNORMAL 
 +4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature (rectal) >41 30-40.9  38.
5 
-
38.
9 
36-
38.4 
34-35.9 32-33.9 30-31.9 <29.9 
MAP= (2xdaistolic+ 
systolic)/3 
>160 130-159 110-
129 
 70-
109 
 50-69 40-54 <49 
Heart rate >180 140-179 110-
139 
 70-
109 
 55-69 40-54 <39 
Respiratory rate  >50 35-49  25 
-34 
12-
24 
10-11 6-9  <5 
Oxygenation 
FiO2>0.5 then A-aDO2 
FiO2<0.5 then PaO2 
>500 350-499 200-
349 
 <200 
 
PO2  
 
>70 
PO2 61-
70 
 pO2  
55-60 
pO2 <55 
Arterial pH/serum  
Bicarb if no ABG avail. 
>7.7/>52 7.6-7.69/ 
 41-51.9 
 7.5 
-
7.5
9/ 
 32 
-
40.
9 
7.33- 
7.49 
/ 22. 
31.9 
 7.25 
-7.32 
/ 18-
21.9 
7.15-
7.24 
/ 15-
17.9 
<7.15/ 
<15 
Na >180 160-179 155-
159 
15
0- 
15
4 
130 
-149 
 120-
129 
111-
119 
<110 
K >7 6-6.9  5.5 
-5. 
3.5-
5.4 
3-3.4 2.5-2.9  <2.5 
Creat >3.5 2-3.4 1.5-1.9  0.6-
1.4 
 <0.6   
Haematocrit >60  50-
59.9 
46 
-
49.
9 
30-
45.9 
 20-29.9  <20 
WBC count >40  20- 15- 3-  1-2.9  <1 
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39.9 19.
9 
14.9 
GCS 
(15-actual GCS)= 
 The Score  
         
 
Age points (years): <44=0, 45-54= 2, 55-64= 3, 65 to 74= 4, > 75 = 5.  
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6. OUTCOMES 
The following parameters were specifically assessed in this study. 
6.1 PRIMARY OUTCOMES  
PRIMARY OUTCOME 
1. Death 
2. Duration of stay in ICU/HDU and duration of hospitalization 
6.2 SECONDARY OUTCOMES 
1. Supervening complications un related to the underlying medical condition 
 
 
 
 
 
. 
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7. DATA ANALYSIS AND STATISTICAL 
METHODS 
 
Data entry was done by the principal investigator in Microsoft Excel Spreadsheet (Annexure 
4). The quantitative variables will be assessed using mean or standard deviation, and median 
with inter quartile ranges. The variables at admission will be correlated with the outcome 
variables using Chi square test. 
The clinical severity score, APACHE score will be analysed in relation to the outcome using 
logistic regression analysis.  
All analysis was performed using SAS version 9.4. 
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8. FUNDING AND APPROVAL 
8.1 Funding Source 
No funding was required for this study as all the investigations and treatment regimens were 
decided by the treating physician. 
 
 8.2 Institutional Research Board approval and ethical considerations 
The research proposal was discussed by the Institutional Review Board in April 2014, and 
approval was obtained [IRB Min No: 8838 dated 07.04.2014] 
There were no ethical issues related to this study.    
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9. RESULTS 
 
9.1 OVERALL CHARECTERISTICS OF THE STUDY POPULATION 
9.1.1 DEMOGRAPHIC CHARACTERISTICS 
A total of 135 adult patients more than 16 years of age, with community acquired infections 
admitted into medical intensive care unit and medical high dependency unit were evaluated. 
There were 107 patients in the retrospective study and 28 patients in the prospective study. 
The mean age (+_SD) was 52.85 (16.81) with a range of 16 - 87 years. There was male 
preponderance (Figure 3). The mean duration of stay in the hospital (+_SD) was 11.21 days 
(8.07) with a range of 1-58 days. The mean duration of stay in the medical intensive care 
unit/medical high dependency unit (+_ SD) was 6.07 days (4.16) with a range of 1-28 days. 
 
Fig 2.Sex distribution in the study population 
9.1.2 PROFILE OF COMORBID ILLNESS 
The most common co-morbid illness seen was diabetes in 63 patients (46.67%). Other 
common comorbid conditions included hypertension, IHD and chronic obstructive airway 
73, 54% 
62, 46% 
SEX N=135 
MALE
FEMALE
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disease. 2 out of the 135 subjects were pregnant. The profile of comorbid illness is 
summarised below in table 3. 
Table 3. Profile of co morbid illnesses in the study population 
Variable Number % 
Diabetes Mellitus 
 
63 
 
46.7 
 
Hypertension 
 
44 
 
32.6 
 
Ischemic Heart Disease 
 
9 
 
6.7 
 
Chronic obstructive airway disease 
  
8 
 
5.9 
  
Chronic Liver Disease 
 
3 
 
2.2 
 
Chronic Kidney Disease 
 
3 
 
2.2 
 
Asthma 
 
2 
 
1.5 
 
 
9.1.3 SUMMARY OF CLINICAL SYMPTOMS 
 
The most common presenting symptom was fever which was present in all the patients. The 
median duration of fever prior to presentation was 7 days with minimum of 2 days to 
maximum of 12 days. 91.1 % reported breathing difficulty at presentation and 59.3 % 
reported cough at presentation .Altered sensorium was present in 28.2% which included 
drowsiness, decreased verbalisation or irrelevant speech, inadequate response to call or 
commands. Ten patients had seizures at presentation, which was of generalised tonic clonic 
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convulsions semiology requiring anti-epileptic therapy. Neither of these patients had focal 
neurological deficits. 
 
Fig. 3 - Summary of clinical symptoms in the study population at admission 
 
9.1.4 SUMMARY OF CLINICAL SIGNS 
 
Fever was present in all patients (n = 135). 9 patients had features of systemic inflammatory 
response (6.7%), 15 presented with features of sepsis (11.1%), 93 had septic shock (68.9%), 
and 18 presented with severe sepsis (13.3%). 
Table 4. Summary of clinical signs in the study population at admission 
Variable Mean SD Minimum Maximum 
Pulse Rate(/min) 112.6 11.9 82 144 
Respiratory rate(/min) 31.41 7.2 20 62 
Temperature (deg.F.) 101.460 1.9635 95.7 105 
Systolic blood pressure(mm Hg) 92.24 12.43 40 120 
Diastolic blood pressure(mm 
Hg) 
58.41 13.53 10 82 
Pulse oximeter (%) 91.21 6.4 60 100 
100% 
91.11% 
28.15% 
7.40% 
4.40% 
14.81% 
8.89% 
0%
20%
40%
60%
80%
100%
120%
Fever
Respiratory
distress
Altered sensorium
Seizures
Bleeding
manifestations
Dysuria
Flank pain
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9.1.5 SUMMARY OF LABORATORY INVESTIGATIONS IN THE STUDY 
POPULATION 
 
9.1.5.1 SUMMARY OF HAEMATOLOGICAL PARAMETERS 
 
Severe anaemia (<7g/dl) was noted in 3.7% of the patients, while mild to moderate anemia 
(7-10g/dl) was seen in 62.9 %, with mean haemoglobin of 11.42 gm/dl.  62.9 % of the 
patients had thrombocytopenia, which was found to be the most common haematological 
abnormality. Leucopoenia was seen in 1.5%, while leucocytosis was seen in 54%. 20.8% 
(n=28) required transfusion of blood products most commonly packed cells. 5 patients 
required multiple units of fresh frozen plasma and 4 received cryoprecipitate. 
Table 5 Summary of haematological parameters in the study population  
Variable Mean SD Minimum Maximum 
Haemoglobin(gm/dl 11.42 2.24 6 19 
Total leucocyte counts(cu mm) 16490.96 23497.94 900 215000 
Platelets(/cu mm) 106007.4 120588.14 3000 795000 
 
9.1.5.2 SUMMARY OF BIOCHEMICAL PARAMETERS 
Among the metabolic derangements, liver injury was the most common biochemical 
abnormality with predominantly transaminitis in SGOT being elevated in 110 patients and 
SGPT in 72 patients. Acute kidney injury was seen in 66.67% (n = 90), with maximum 
value noted to 9.4 gm/dl. Hypoalbuminemia was seen in 91.9 % (n=124), a mean of 2.63 
g/dl.  
The summary of the biochemical parameters is in table.. 
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Table 6. Summary of biochemical parameters in the study population  
Variable Mean SD Minimum Maximum 
Creatinine(mg/dl) 2.5 1.77 0.57 9.44 
Total Bilirubin(mg/dl) 2.15 1.92 0.2 13 
Direct Bilirubin (mg %) 1.52 1.63 0.1 11 
Total protein(gm/dl) 6.06 1 1.7 8.2 
Albumin(gm/dl) 2.63 0.66 0.5 4.4 
SGOT(U/l) 148.44 180.78 11 1416 
SGPT(U/l) 63.36 68.35 1 521 
Alkaline phosphatase(U/l) 174.69 105.81 33 517 
 
9.1.5.3 SUMMARY OF MICROBIOLOGICAL PARAMETERS 
 75.6% of the blood culture was sterile and growth was noted in 24.4% of the patients. The 
most common organism isolated was extended spectrum beta lactamase producing 
Escherichia coli (54.5%), followed by non ESBL E.coli (12.1%), S. Pneumonia (12.1%), and 
Klebsiella sp (9.1%). 
 Urine culture grew organisms in 14.81 % of the patients with the most common organism 
being extended spectrum beta lactamase producing Escherichia coli (11.9%).  
Sputum gram stain in 3 patients with community acquired pneumonia grew organisms, which 
was subsequently isolated in the cultures. The organisms isolated were Streptococcus 
pneumonia, methicillin resistant Staphylococcus aureus and Pseudomonas aeruginosa.   
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Fig 4.Growth on blood culture in the study population 
 
 
Fig 5.Distribution of organisms isolated in blood culture 
 
9.2 SPECTRUM OF COMMUNITY ACQUIRED INFECTIONS 
The most common infection was scrub typhus, and it was seen in 75 out of 135 of the 
patients. Followed by pyelonephritis which was reported in 20 patients and community 
acquired pneumonia in 12 patients. 4 out of the 135 had bacteremia where the source of the 
bacteremia could not be identified and 8 had undifferentiated febrile illness where the 
24.44% 
75.56% 
Blood culture positivity N=135 
Growth n=33
No growth n=102
18, 55% 
4, 12% 
4, 12% 
3, 9% 
1, 3% 
1, 3% 
1, 3% 
1, 3% 
Organisms isolated from blood culture n=33 
Escherichia coli
(ESBL)
Escherichia coli
Streptococcus
pneumoniae
Klebsiella
Enterobacter
Group E
Salmonella
Salmonella typhi-
NARST
MRSA
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diagnosis could not be ascertained. Other infections included soft tissue infection, Dengue, 
Viral encephalitis, Malaria, Typhoid, pyogenic meningitis and acute gastroenteritis. 
Table 7 Clinical spectrum of community acquired infections 
FINAL DIAGNOSIS RETROS
PECTIV
E 
(n=107) 
PROSPE
CTIVE 
(n=28) 
TOTAL 
N=135 
Percent 
(%) 
Scrub typhus 62 13 75 55.6 
Pyelonephritis 13 7 20 14.9 
Community acquired pneumonia 10 2 12 8.9 
Acute febrile illness without cause (AFI) 7 1 8 5.9 
Bacteremia without source 4 0 4 2.9 
Soft tissue infections 4 0 4 2.9 
Dengue 2 1 3 2.2 
Viral encephalitis 2 1 3 2.2 
Pyogenic meningitis 2 0 2 1.5 
Enteric fever 0 2 2 1.5 
Malaria 0 1 1 0.7 
Acute gastroenteritis 1 0 1 0.7 
 
 
 Fig 6.  Distribution of clinical spectrum of community acquired infections N=135 
75, 56% 
20, 15% 
12, 9% 
8, 6% 
4, 3% 
4, 3% 
3, 2% 
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MALARIA
ACUTE GASTROENTERITIS
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9.3 ETIOLOGY/MICROBIOLOGY OF INDIVIDUAL INFECTIONS 
 
9.3.1 PYELONPHRITIS 
 
Out of 20 patients with pyelonephritis, 18 were found to have bacteremia. The most common 
organism isolated was extended spectrum beta lactamase producing Escherichia coli (83.3%). 
The others included non ESBL E.coli (11.1%) and Klebsiella (5.5%). In 14 (77.8%) patients 
extended spectrum beta lactamase producing Escherichia coli was isolated from urine culture. 
Table 8 Etiology of pyelonephritis (isolate from blood culture) (n=20) 
VARIABLE BLOOD CULTURE 
ISOLATE 
Growth on blood culture 
n=20 
18 90% 
Escherichia coli (ESBL) 
n=18 
15 83.3% 
Escherichia coli n=18 2 11.1% 
Klebsiella n=18 1 5.5% 
No growth n=20 2 10% 
 
Table 9. Etiology of pyelonephritis (isolate from urine culture) (n=20) 
VARIABLE URINE CULTURE 
ISOLATE 
Growth on urine  culture 
n=20 
18 90% 
Escherichia coli (ESBL) 
n=18 
14 77.8% 
Escherichia coli n=18 2 11.1% 
Klebsiella n=18 2 11.1% 
No growth n=20 2 10% 
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9.3.2 COMMUNITY ACQUIRED PNEUMONIA 
 
4 patients with community acquired pneumonia had bacteremia, with Streptococcus 
pneumoniae being isolated in 25% of cases. Methicillin resistant staphylococcus aureus was 
isolated from the blood and sputum in 1 patient. 
Table 10. Etiology of community acquired pneumonia (isolates from blood culture) 
(n=12) 
VARIABLE BLOOD CULTURE 
ISOLATE 
BLOOD CULTURE 
POSITIVE 
4 33.3% 
Streptococcus pneumoniae 3 75% 
Pseudomonas 0  
Methicillin resistant 
Staphylococcus aureus 
1 25% 
NO GROWTH 8 66.7% 
 
Table 11.Etiology  of community acquired pneumonia (isolates from sputum culture) 
(n=12) 
VARIABLE SPUTUM GRAM STAIN 
AND CULTURE 
SPUTUM CULTURE 
POSITIVE 
3 25% 
Streptococcus pneumoniae 1 8.3% 
Pseudomonas 1 8.3% 
Methicillin resistant 
Staphylococcus aureus 
1 8.3% 
NO GROWTH 9 75% 
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9.3.3 BACTEREMIA OF UNKNOWN SOURCE 
 
4 patients had bacteremia with no source of infection identified. Of the 4 patients, 2 had 
E.coli bacteremia. The other 2 organisms isolated included Klebsiella and Enterobacter. 
Table 12. Etiology of bacteremia with unknown source (n=4) 
Variable BLODD CULTURE ISOLATE 
 Escherichia coli 2 50% 
Klebsiella 1 25% 
Enterobacter 1 25% 
 
9.3.4 SKIN AND SOFT TISSUE INFECTION 
4 patients had skin and soft tissue infection, and 3 of them had bacteremia. 
The organisms isolated included E.coli, Klebsiella and Streptococcus pneumoniae 
Table 13. Etiology of skin and soft tissue infections (n=4) 
VARIABLE BLOOD CULTURE ISOLATES n=4 
Escherichia. Coli 1 25% 
Klebsiella 1 25% 
streptococcus pneumoniae 1 25% 
No growth 1 25% 
 
9.3.5 ENTERIC FEVER 
2 patients were diagnosed to have enteric fever, and the organisms isolated was group E 
Salmonella in 1 and Nalidixic acid resistant Salmonella typhi in the other 
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9.3.6 SEROLOGICAL PARAMETERS 
Scrub IgM ELISA was sent for 68 patients out of 75 and was positive in all 68 (90.7%). 
Dengue infection was identified in 3 patients, and Dengue IgM was positive in 2 patients. 
One patient was identified to have malaria and the smear was positive for Plasmodium 
falciparum. 
9.3.7 ACUTE CENTRAL NERVOUS SYSTEM INFECTIONS 
5 patients were noted to have acute CNS infection. Of these 3 were diagnosed to have viral 
encephalitis. CSF multiplex PCR was negative in 2 patients, but they had radiological 
features consistent with temporal lobe involvement. 
2 patients were identified to have pyogenic meningitis. Of which one was diagnosed to have 
meningococcal meningitis as Latex agglutination of the CSF tested positive for Neisseria 
meningitidis. In the other patient, no organism was isolated from CSF. 
9.4. ADMISSION CORRELATES OF SPECIFIC CLINICAL SYNDROMES 
Among the 12 infections identified the 3 most common infections were scrub typhus, 
pyelonephritis and community acquired pneumonia. Hence the admission correlates of these 
diagnoses will be presented. 
9.4.1 CORRELATION OF SEX WITH SCRUB TYPHUS, PYELONEPHRITIS, AND 
COMMUNITY ACQUIRED PNEUMONIA 
Of the 75 cases of scrub typhus, 56 % were females. 55% of the patients with pyelonephritis 
were males and 67% of the cases with community acquired pneumonia were males. 
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Fig 7. Sex distribution among the patients with scrub typhus, pyelonephritis, and 
community acquired pneumonia. 
 
9.4.2 CORRELATION OF AGE WITH SCRUB TYPHUS, PYELONEPHRITIS, AND 
COMMUNITY ACQUIRED PNEUMONIA 
Scrub typhus was seen in 52% of patients above the age of 51 years, while 48 % as less than 
50 years. Only one patient (5%) with pyelonephritis was less than 50 years. Of the 12 patients 
with community acquired pneumonia, 9 were more than 51 years of age (75%). 
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Fig . Distribution of age among the patients with scrub typhus, pyelonephritis, and 
community acquired pneumonia 
 
9.4.3 CORRELATION OF CO-MORBIDITIES WITH SCRUB TYPHUS, 
PYELONEPHRITIS, AND COMMUNITY ACQUIRED PNEUMONIA 
 9.4.3.1 SCRUB TYPHUS 
The most common co-morbidity seen was diabetes mellitus (32%), while hypertension was 
reported in 14.7% of the 75 cases of scrub typhus. 
Table 14. Profile of co-morbid conditions in patients with scrub typhus 
 
VARIABLE, n=75 FREQUENCY  PERCENTAGE (%) 
Diabetes mellitus 24 32 
Hypertension 11 14.7 
Chronic obstructive 
pulmonary disease 
1 1.3 
Asthma 1 1.3 
Ischemic heart disease 2 2.7 
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9.4.3.2 PYELONEPHRITIS 
 
17 patients diagnosed with pyelonephritis had diabetes mellitus (85%), while only 2 patients 
(10%) were known to have underlying chronic kidney disease. 
Table 15. Profile of co-morbid conditions in patients with pyelonephritis 
VARIABLE, n=20 FREQUENCY PERCENTAGE (%) 
Diabetes mellitus 
17 85 
Hypertension 
14 70 
Ischemic heart disease 
3 15 
Chronic liver disease 2 10 
chronic kidney disease 2 10 
Chronic obstructive 
pulmonary disease 
1 5 
HIV 1 5 
 
9.4.3.3 COMMUNITY ACQUIRED PNEUMONIA 
Of the 12 patients, 9 patients had Diabetes Mellitus, 4 patients had underlying chronic 
pulmonary disease, while 1 patient had bronchial asthma. 
Table 16. Profile of co-morbid conditions in patients with community acquired 
pneumonia 
VARIABLE FREQUENCY, n=12 PERCENTAGE (%) 
Diabetes mellitus 
9 75 
Hypertension 
7 58.3 
Chronic obstructive 
pulmonary disease 
4 33.3 
Ischemic heart disease 
3 25 
Asthma 
1 8.3 
Smoking 
6 50 
Alcohol 2 16.7 
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9.4.4 CORRELATION OF CLINICAL SYMPTOMS WITH SCRUB TYPHUS, 
PYELONEPHRITIS, AND COMMUNITY ACQUIRED PNEUMONIA  
9.4.4.1 SUMMARY OF THE CLINICAL SYMPTOMS IN SCRUB TYPHUS 
The commonest symptom was fever which was present in all 75 patients. Of the 75, 96% 
patients presented with breathlessness requiring respiratory support. 22.7% of the patients 
presented with altered sensorium and 3 had seizures as well. 
 
Fig 9 Distribution of clinical symptoms in patients  with scrub typhus 
9.4.4.2 SUMMARY OF CLINICAL SYMPTOMS IN PATIENTS WITH 
PYELONEPHRITIS 
The most common symptom was fever, which was seen in all 20 patients and dysuria was 
seen in all 20 cases, but flank pain was reported only in 60%. Additionally 30% of the 
patients had altered sensorium 
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Fig 10. Distribution of clinical symptoms in patients with pyelonephritis 
9.4.4.3 SUMMARY OF CLINICAL SYMPTOMS IN PATIENTS WITH 
COMMUNITY ACQUIRED PNEUMONIA 
All 12 patients with community acquired pneumonia had fever with cough and productive 
cough. All 12 presented with breathing difficulty as well. 
 
Fig 11. Distribution of clinical symptoms in patients with community acquired 
pneumonia 
20 
20 
17 
16 
12 
6 
0 5 10 15 20 25
FEVER
DYSURIA
BREATHLESNESS
VOMIITING
FLANK PAIN
ALTERED SENSORIUM
CLINICAL SYMPTOMS IN PATIENTS WITH PYELONEPHRITIS n=20 
CLINICAL SYMPTOMS IN
PATIENTS WITH
PYELONEPHRITIS n=20
12 
12 
12 
0 5 10 15
FEVER
BREATHLESNESS
COUGH
CLINICAL SYMPTOMS IN PATIENTS WITH COMMUNITY ACQUIRED 
PNEUMONIA n=12 
CLINICAL SYMPTOMS IN
PATIENTS WITH COMMUNITY
ACQUIRED PNEUMONIA n=12
Page | 70  
 
 
9.4.5 CORRELATION OF CLINICAL SIGNS WITH SCRUB TYPHUS, 
PYELONEPHRITIS, AND COMMUNITY ACQUIRED PNEUMONIA  
9.4.5.1 SUMMARY OF THE CLINICAL SIGNS IN SCRUB TYPHUS 
62 patients (83%) with scrub typhus had heart rate more than 101 beats per minute, ranging 
between 102 to 144 beats per minute.39 patients had systolic blood pressure more than 90 
mmHg, ranging between 92 mmHg and 110 mmHg.  36 patients had systolic blood pressure 
less than 90 mmHg, with the lowest recorded systolic blood pressure of 60 mmHg. 31 
patients had diastolic blood pressure less than 40 mmHg. 
68 patients had tachypnea with maximum respiratory rate of 62 beats per minute. 26 patients 
had saturation less than 90 %. 62 out of 75 patients were noted to have eschar. 
Table 17. Summary of clinical signs in patients with scrub typhus 
VARIABLE FREQUENCY PERCENTAGE 
Heart rate <100 bpm 36 48 
Heart rate >101 bpm 39 52 
Respiratory  
rate <24 bpm 
31 41 
Respiratory  
rate >25 bpm 
44 59% 
SBP < 90 mmHg 36 48% 
SBP > 91 mmHg 39 52% 
DBP  < 60 mmHg 31 41% 
DBP  > 61 mmHg 44 59% 
SaO2 < 90 mmHg 26 35% 
SaO2 > 91 mmHg 49 65% 
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Fig 12 Distribution of eschar in patients with scrub typhus 
 
9.4.5.2 SUMMARY OF THE CLINICAL SIGNS IN PYELONEPHRITIS 
15 patients with pyelonephritis had heart rate more than 101 beats per minute, with maximum 
heart rate of 128 beats per minute. 10 patients had systolic blood pressure less than 90 mmHg 
and 15 patients had diastolic blood pressure less than 40 mmHg. 
Table 18.Summary of clinical signs in patients with pyelonephritis 
VARIABLE FREQUENCY PERCENTAGE 
Heart rate <100 
bpm 
10 50% 
Heart rate >101 
bpm 
10 50% 
Respiratory  
rate <24 bpm 
5 25% 
Respiratory  
rate >25 bpm 
15 75% 
SBP < 90 mmHg 10 50% 
SBP > 91 mmHg 10 50% 
DBP  < 60 mmHg 5 25% 
DBP  > 61 mmHg 15 75% 
SaO2 < 90 mmHg 26 35% 
SaO2 > 91 mmHg 49 65% 
62, 83% 
13, 17% 
Presence of eschar in patients with scrub 
typhus n=75 
ESCHAR PRESENT
NO ESCHAR
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Fig 13 Distribution of presence of renal angle tenderness in patients with pyelonephritis 
 
9.4.5.3 SUMMARY OF THE CLINICAL SIGNS IN COMMUNITY ACQUIRED 
PNEUMONIA 
11 patients with CAP had heart rate more than 101 beats per minute, with maximum heart 
rate of 124 beats per minute. 10 patients had systolic blood pressure less than 90 mmHg and 
25 patients had diastolic blood pressure less than 40 mmHg. All 12 had tachypnea with 
respiratory rate of more than 24 beats per minute.8 patients had saturation less than 90 %. 
Table 19. Summary of clinical signs in patients with community acquired pneumonia 
VARIABLE FREQUENCY PERCENTAGE 
Heart rate <100 
bpm 
8 67% 
Heart rate >101 
bpm 
4 33% 
Respiratory  
rate <24 bpm 
2 17% 
Respiratory  
rate >25 bpm 
10 83% 
SBP < 90 mmHg 8 67% 
SBP > 91 mmHg 4 33% 
12, 60% 
8, 40% 
RENAL ANGLE TENDERNESS n=20 
Renal angle
tenderness
present
No renal angle
tenderness
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DBP  < 60 mmHg 2 17% 
DBP  > 61 mmHg 10 83% 
SaO2 < 90 mmHg 8 67% 
SaO2 > 91 mmHg 4 33% 
 
9.4.6 CORRELATION OF LABORATORY ABNORMALITIES WITH SCRUB 
TYPHUS, PYELONEPHRITIS, AND COMMUNITY ACQUIRED PNEUMONIA  
9.4.6. 1 HEMATOLOGICAL ABNORMALITIES IN SCRUB TYPHUS 
Leucocytosis was seen in 44 % of the patients with scrub typhus.  64 patients had 
thrombocytopenia, of these 17 patients had severe thrombocytopenia with platelet counts less 
than 20,000 cells/mm3. 
Table 20.Summary of hematological abnormalities in patients with scrub typhus, 
 
VARIABLE FREQUENCY PERCENTAGE 
< 4000 cell/mm3 1 1.3% 
4001- 11,000 
cells/mm3 
41 54.7% 
>11,001 cells/mm3 33 44% 
< 7g/dl  2.7% 
7.1-12g/dl 47 62.7% 
>12.1 g/dl 26 34.7% 
<50,000 MM3 43 57.3% 
50,001-100,000 
MM3 
21 28% 
>100,001 MM3 11 14.7% 
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9.4.6.2 HEMATOLOGICAL ABNORMALITIES IN PYELONEPHRITIS 
 
85% of patients with pyelonephritis had WBC counts more than 11,000 cells/mm3, and 
thrombocytopenia was seen in 45 % of the patients.  
Table 21.Summary of hematological abnormalities in patients with pyelonephritis 
 
VARIABLE FREQUENCY PERCENTAGE 
< 4000 cell/mm3 0  
4001- 11,000 
cells/mm3 
3 15% 
>11,001 cells/mm3 17 85% 
< 7g/dl 1 5% 
7.1-12g/dl 16 80% 
>12.1 g/dl 3 15 
<50,000 MM3 2 10% 
50,001-100,000 
MM3 
7 35% 
>100,001 MM3 11 55% 
 
9.4.6.3 HEMATOLOGICAL ABNORMALITIES IN COMMUNITY ACQUIRED 
PNEUMONIA 
9 patients with community acquired pneumonia had WBC count more than 11,001 
cells/mm3. The platelet counts were more than 100,000 cells/mm3 in all patients. 
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Table 22.Summary of hematological abnormalities in patients with community acquired 
pneumonia 
VARIABLE FREQUENCY PERCENTAGE 
< 4000 cell/mm3 0  
4001- 11,000 
cells/mm3 
3 25% 
>11,001 cells/mm3 9 75% 
< 7g/dl 0  
7.1-12g/dl 7 58.3% 
>12.1 g/dl 5 41.7% 
<50,000 MM3 1 8.3% 
50,001-100,000 
MM3 
0  
>100,001 MM3 11 91.7% 
 
9.4.6.4 BIOCHEMICAL ABNORMALITIES IN SCRUB TYPHUS 
 
44 patients had acute kidney injury with maximum creatinine value of 9.44 mg/dl. Liver 
enzymes were deranged, with 73 patients had elevated SGOT, ranging between 41 IU to 512 
IU and 53 patients had elevated SGPT, with the maximum value of 200 IU.  
Table 23. Summary of biochemical abnormalities in patients with scrub typhus 
VARIABLE FREQUENCY PERCENTAGE 
<1.4 g/dl 31 41.3% 
>1.5 g/dl 44 58.7% 
SGOT <40 IU 2 2.7% 
SGOT >41IU 73 97.3% 
SGPT <40 IU 22 29.3% 
SGPT >40 IU 53 70.7% 
 
Page | 76  
 
9.4.6.5 BIOCHEMICAL ABNORMALITIES IN PYELONEPHRITIS 
 
All patients with pyelonephritis had acute kidney injury with 80 % had creatinine more than 
2.1 g/dl. 
Table 24 summary of biochemical abnormalities in patients with community acquired 
pneumonia 
VARIABLE FREQUENCY PERCENTAGE 
<1.4 g/dl 0  
>1.5 g/dl 20 100% 
SGOT <40 IU 10 50% 
SGOT >41IU 10 50% 
SGPT <40 IU 15 75% 
SGPT >40 IU 5 25% 
 
9.4.6.6 BIOCHEMICAL ABNORMALITIES IN COMMUNITY ACQUIRED 
PNEUMONIA 
Serum creatinine was elevated in 8 patients. The liver enzymes, SGOT and SGPT were 
elevated in 5 and 2 patients respectively. 
Table 25. Summary of biochemical abnormalities in patients with community acquired 
pneumonia 
VARIABLE FREQUENCY PERCENTAGE 
<1.4 g/dl 4 33.3% 
>1.5 g/dl 8 66.7% 
SGOT <40 IU 7 58.3% 
SGOT >41IU 5 41.7% 
SGPT <40 IU 10 83.3% 
SGPT >40 IU 2 16.7% 
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9.4.7 APACHE II SCORE IN PATIENTS WITH COMMUNITY ACQUIRED 
INFECTIONS 
16 patients with scrub typhus had APACHE II score more than 11, of which 5 patients had 
score more than 26 and the maximum score was 35.  
1 patient with pyelonephritis had APACHE II score more than 35, while 7 had scores 
between 26- 34. The maximum noted score was 41. 
7 patients with community acquired pneumonia had score between 11- 25, while 1 had score 
of 27 which was the maximum noted APACHE II score in this study population. 
Table 26. Summary of APCHE II SCORE in patients with scrub typhus, pyelonephritis 
and community acquired pneumonia 
VARIABLE APACHE II 
SCORE < 10 
APACHE II 
SCORE 11-25 
APACHE II 
SCORE  
 26- 34 
APACHE II 
SCORE > 35 
MISSING 
DATA 
 FREE
QUE
NCY 
PERC
ENT 
FRE
QUE
NCY 
PERC
ENT 
FRE
QUE
NCY 
PERCEN
T 
FREQ
UENC
Y 
PERCEN
T 
FREQ
UENC
Y  
PERC
ENT 
SCRUB 
TYPHUS 
n=75 
8 11% 55 73% 5 7% 0  7 9% 
 
PYELONEP
HRITIS n=20 
1 5% 10 53% 7 37% 1 5% 1 5% 
COMMUNIT
Y 
ACQUIRED 
PNEUMONI
A 
n=12 
0  7 59 1 8%   4 33% 
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9.4.8 ORGAN SYSTEM FAILURE IN SCRUB TYPHUS, PYELONEPHRITIS, 
COMMUNITY ACQUIRED PNEUMONIA 
9.4.8.1 SUMMARY OF ORGAN SYSTEM FAILURE IN SCRUB TYPHUS 
Acute respiratory distress syndrome was seen in 70 patients, while renal failure was seen in 
64 patients. Shock requiring inotropes was seen in 64 patients. 
Table 27. Summary of organ system failure in patients with scrub typhus 
VARIABLE FREQUENCY n=75 PERCENTAGE 
ACUTE RESPIRATORY 
DISTRESS SYNDROME 
70 93.3 
SEPTIC SHOCK 64 85.3 
ACUTE KIDNEY INJURY 45 60 
 
 
9.4.8.2. SUMMARY OF ORGAN SYSTEM FAILURE IN PYELONEPHRITIS 
All 20 patients had acute kidney injury and septic shock, while 18 patients had acute 
respiratory distress syndrome 
Table 28. Summary of organ system failure in patients with 
Pyelonephritis 
VARIABLE FREQUENCY n=20 PERCENTAGE % 
ACUTE RESPIRATORY 
DISTRESS SYNDROME 
18 90 
SEPTIC SHOCK 20 100 
ACUTE KIDNEY INJURY 20 100 
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9.4.8.3 SUMMARY OF ORGAN SYSTEM FAILURE IN COMMUNITY ACQUIRED 
PNEUMONIA 
All 12 patients had acute respiratory distress syndrome and septic shock. 8 patients out of 12 
had acute kidney injury. 
Table 29. Summary of organ system failure in patients with 
Community acquired pneumonia 
VARIABLE FREQUENCY n=12 PERCENTAGE 
ACUTE RESPIRATORY 
DISTRESS SYNDROME 
12 100 
SEPTIC SHOCK 12 100 
ACUTE KIDNEY INJURY 8 66.7 
 
9.5 CHOICE OF ANTIBIOTICS FOR INDIVIDUAL COMMUNITY ACQUIRED 
INFECTIONS 
Doxycyline was the antibiotic of choice in 72 patients with scrub typhus, and 63 patients 
received azithromycin in addition. Azithromycin alone was given in 3 patients, of which one 
patient was a pregnant lady. 
In patients with pyelonephritis, meropenem was used in 16 patients, while ertapenem was 
administered to 1 patient. 2 patients received Pipericillin- tazobactum, in addition to 
meropenem and in one patient Pipericillin tazobactum alone was used. 
The choice of antibiotics varied in patients with community acquired pneumonia. 3 patients 
received combination of azithromycin and Pipericillin tazobactum, 2 received Pipericillin 
tazobactum and meropenem, 1 patient received Pipericillin-tazobactum and 2 patients were 
treated with meropenem alone. One patient who had MRSA was given Vancomycin, however 
the first choice of antibiotic prior to availability of the culture reports was Pipericillin-
tazobactum and azithromycin.  
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Fig 14. Distribution of choice of antibiotics in patients with scrub typhus 
 
 
Fig 15. Distribution of choice of antibiotics in patients with pyelonephritis 
63, 84% 
9, 12% 
3, 4% 
Choice of antibiotics in scrub typhus n=75 
Doxycycline and
Azithromycin
Doxycycline
Azithromycin
16, 80% 
2, 10% 
1, 5% 
1, 5% 
Choice of antibiotics in patients with pyelonephritis 
n=20 
Meropenem
Pipercillin- tazobactum
and meropenam
Ertapenem
Pipercillin- tazobactum
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Fig 16. Distribution of choice of antibiotics in patients with community acquired 
pneumonia 
 
9.6 ORGAN SYSTEM SUPPORT REQUIRED FOR PATIENTS WITH SCRUB 
TYPHUS, PYELONEPHRITIS, COMMUNITY ACQUIRED PNEUMONIA  
9.6.1 REQUIREMENT OF VENTILATORY SUPPORTS IN PATIENTS WITH 
SCRUB TYPHUS, PYELONEPHRITIS, COMMUNITY ACQUIRED PNEUMONIA 
94.7% of patients with scrub typhus required ventilatory support with 55 patients requiring 
invasive ventilation. The duration of ventilatory support requirement ranged from 1 day to 23 
days.   
3, 25% 
2, 17% 
1, 9% 1, 9% 
1, 8% 
1, 8% 
1, 8% 
1, 8% 
1, 8% 
Choice of antibiotics in patients with community acquired pneumonia 
n=12 
Pipercillin tazobactum and
azithromycin
Meropenem
Pipercillin azobactum and
meropenem
Pipercillin tazobactum
azithromycin
pipercillin tazobactum and
augmentin
merpenem and vancomycin
Azithromycin, pipercillin
tazobactum and vancomycin
pipercillin tazobactum,
meropenem and vancomycin
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All 20 patients with pyelonephritis had respiratory distress syndrome and 80% of them 
required invasive ventilation. The duration of ventilatory support requirement ranged from 1 
day to 21 days. 
83.3 % of the patients with community acquired pneumonia required invasive ventilation, 
while 16.7% was managed with non-invasive ventilation. The maximum duration was 14 
days. 
9.6.2 REQUIREMENT OF DIALYSIS IN PATIENTS WITH SCRUB TYPHUS, 
PYELONEPHRITIS, COMMUNITY ACQUIRED PNEUMONIA 
 
6 patients with scrub typhus required renal replacement therapy with haemodialysis. 
50% of patients with acute pyelonephritis required haemodialysis. 
 In the cohort with the diagnosis of community acquired pneumonia, only 2 out 8 with acute 
kidney injury required haemodialysis.  
9.6.3 REQUIREMENT OF INOTROPES IN PATIENTS WITH SCRUB TYPHUS, 
PYELONEPHRITIS, COMMUNITY ACQUIRED PNEUMONIA 
88.9 % of patients in the study required use of inotropes or vasoactive agents due to septic 
shock. The most common inotrope used was dopamine, noradrenaline and adrenaline. In 
patients with scrub typhus, 85.3% of them required inotropes, while all patients among those 
with pyelonephritis and community acquired pneumonia required inotropic support. 
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9.7 NOSOCOMIAL COMPLICATIONS IN COMMUNITY ACQUIRED 
INFECTIONS 
Of the 135 patients, 40 patients developed nosocomial complications, of which 23 patients 
had ventilator associated pneumonia (VAP), 6 had line related catheter associated blood 
stream infection (CRBSI-L) and 6 had urinary catheter associated catheter related blood 
stream infection (CRBSI-U).  
21 patients with scrub typhus developed nosocomial complications of which 12 had VAP, 4 
had CRBSI-U, 2 had CRBSI-L and 1 patient had both VAP and CRBSI-L.  
Among those with community acquired pneumonia, 5 developed nosocomial complications, 
of which 3 had VAP, and 1 had CRBSI-U. 
6 out of 20 patients with pyelonephritis developed nosocomial complications. 
 
Fig17.Distribution of nosocomial complications in the study population 
 
23, 57% 
6, 15% 
6, 15% 
2, 5% 
1, 2% 1, 3% 1, 3% 
Nosocomial complications n=40 
VAP
CRBSI-L
CRBSI-U
Hospita accquired
infection of unknown
source (HAI)
Secondary bacterial
peritonitis (SBP)
VAP and CRBSI-L
GI bleed
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Fig 18 Distribution of nosocomial infections in patients with scrub typhus, 
pyelonephritis, and community acquired pneumonia, n= 32 
 
9.8 MORTALITY RATES IN COMMUNITY ACQUIRED INFECTIONS 
Of the 135 subjects in the study, 35 patients expired. The overall mortality rate was 25.9%. 
The infection specific mortality rates were 13.3% in scrub typhus, followed by pyelonephritis 
(40%) and CAP (41.7%). Early death (within 7 days of hospital admission) occurred in 6 
patients with scrub typhus, 1 patient with pyelonephritis and 3 patients with community 
acquired pneumonia. In scrub typhus, 7 out of the 10 who died were over the age of 50 years.  
Table 30 Infection specific mortality rates of scrub typhus, pyelonephritis, community 
acquired pneumonia 
VARIABLE FREQUENCY INFECTION 
SPECIFIC 
MORTALITY 
RATE 
Scru typhus, n=75 10 13.3% 
Pyelonephritis, n=20 8 40% 
Community acquired 
pneumonia, n=12 
5 41.7% 
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3 
2 2 
4 
1 1 1 
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9.9 DURATION OF HOSPITALISATION  
The median duration of stay in the hospital for patients with scrub typhus was 9 days with a 
range of 1 to 31 days, for patients with pyelonephritis was 10 days with a range of 3 to 58 
days, and for patients with community acquired pneumonia was 10.5 days with a range of 2 
to 40 days. The median duration of stay in the MICU/MHDU was, 5 days for scrub typhus, 7 
days for pyelonephritis and 5.5 days for community acquired pneumonia. 
9.10 CORRELATION OF CLINICAL AND LABORATORY PARAMETERS IN 
PREDICTING THE DIAGNOSIS 
The three most common infections identified in the study population were scrub typhus, 
pyelonephritis and community acquired pneumonia.  
9.10.1 SCRUB TYPHUS 
Presence of fever and eschar was seen in 83%. These parameters predicted the diagnosis of 
scrub typhus. The sensitivity of eschar for diagnosis of Scrub typhus in the ICU setting was 
0.84 and specificity was 1. 
Table 31. Eschar in scrub typhus 
 Eschar present Eschar absent  
Scrub typhus 63 12 75 
No scrub typhus 0 60 60 
TOTAL 63 72 135 
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44% of patients with Scrub typhus had leucocytosis (WBC count>11,000 cell/mm3). The 
sensitivity and specificity of leucocytosis for diagnosis of scrub typhus were 0.44 and 0.317 
respectively. 
Table 32.Leucocytosis in scrub typhus 
 Leucocytosis No leucocytosis  
Scrub typhus 33 42 75 
No scrub typhus 41 19 60 
 74 61 135 
 
Thrombocytopenia (platelet count <100,000 cells/mm3) was present in 85.3% of patients 
with Scrub typhus. The sensitivity and specificity of thrombocytopenia for diagnosis of scrub 
typhus were 0.85 and 0.65 respectively. 
Table 33. Thrombocytopenia in scrub typhus 
 Thrombocytopenia Normal platelets  
Scrub typhus 64 11 75 
No scrub typhus 21 39 60 
 85 50 135 
 
Liver enzyme, SGOT was elevated in 97.3% of patients with scrub typhus. The sensitivity 
and specificity of thrombocytopenia for diagnosis of scrub typhus were 0.97 and 0.38 
respectively. 
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Table 34. Elevated liver enzyme (SGOT) in scrub typhus 
 Elevated SGOT >41IU Normal SGOT <40IU  
Scrub typhus 73 2 75 
No scrub typhus 37 23 60 
 110 25 135 
 
Liver enzyme, SGPT was elevated in 70.6% of scrub typhus. The sensitivity and specificity 
of thrombocytopenia for diagnosis of scrub typhus were 0.7 and 0.68 respectively. 
Table 35. Elevated liver enzyme (SGPT) in scrub typhus 
 Elevated SGPT >41IU Normal SGPT <40IU  
Scrub typhus 53 22 75 
No scrub typhus 19 41 60 
 72 63 135 
 
The clinical signs and laboratory tests with the highest sensitivity for diagnosis of scrub 
typhus were Eschar (0.84), thrombocytopenia (0.85) and elevated SGOT (0.97). The clinical 
signs with highest specificity for diagnosis of scrub typhus were Eschar (1), 
thrombocytopenia (0.65) and elevated SGOT (0.68). 
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9.10.2 PYELONEPHRITIS 
The sensitivity and specificity of dysuria for diagnosis of pyelonephritis in ICU was 1 and 1. 
Table 36. Dysuria in pyelonephritis 
 Dysuria No dysuria  
Pyelonephritis 20 0 20 
No pyelonephritis 0 115 115 
 20 115 135 
 
The sensitivity and specificity of renal angle tenderness for diagnosis of pyelonephritis in 
ICU was 0.6 and 1. 
Table 37. Renal angle tenderness in pyelonephritis 
 Renal angle 
tenderness + 
No renal angle 
tenderness 
 
Pyelonephritis 12 8 20 
No pyelonephritis 0 115 115 
 12 123 135 
 
Dysuria had a sensitivity for 1 for diagnosis of pyelonephritis and dysuria and renal angle 
tenderness had specificity of 1 for diagnosis of pyelonephritis. 
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9.10.3 COMMUNITY ACQUIRED PNEUMONIA 
The sensitivity and specificity of cough for diagnosis of community acquired pneumonia in 
ICU was 1 and 0.45. 
Table 38. Cough in Community acquired pneumonia 
 COUGH + NO COUGH  
CAP 12 0 12 
No CAP 68 55 123 
 80 55 135 
 
The sensitivity and specificity of breathlessness for diagnosis of community acquired 
pneumonia in ICU were 1 and 0.09 respectively. 
Table 39. Breathlessness in community acquired pneumonia 
 breathlessness  + No  breathlessness   
CAP 12 0 12 
No CAP 111 12 123 
 123 12 135 
 
The sensitivity and specificity of chest x-ray findings for diagnosis of community acquired 
pneumonia in ICU were 0.67 and 1 respectively. 
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Table 40. Patch on Chest X ray in community acquired pneumonia 
 Patch on chest xray + No  patch on chest 
xray   
 
CAP 8 4 12 
No CAP 0 123 123 
 8 127 135 
 
The sensitivity of cough and chest x-ray findings for diagnosis of community acquired 
pneumonia in the ICU was 1 and 0.67 and specificity of chest x-ray for diagnosis of 
community acquired pneumonia was 1. 
9.11 PREDICTORS OF MORTALITY 
The age of diagnosis was not statistically significant in neither of the 3 infections.  
Table 41 Age and scrub typhus 
 ALIVE DEATH  
AGE <50 YEARS 33 3 36 
AGE >50 YEARS 32 7 39 
 65 10 75 
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Table 42. age and pyelonephritis 
 ALIVE DEATH  
AGE <50 YEARS 1 0 1 
AGE >50 YEARS 11 8 19 
 12 8 20 
            
Table 43 Age and Community acquired pneumonia 
 ALIVE DEATH  
AGE <50 YEARS 3 1 4 
AGE >50 YEARS 4 4 8 
 7 5 12 
 
In patients with pyelonephritis, 17 patients had diabetes mellitus. The presence of diabetes 
mellitus as a co-morbidity was compared with the outcome of death in this sub group and this 
was found to be statistically significant. But presence of underlying chronic kidney disease 
(CKD) was not found to be significant. 
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Table 44. Diabetes and pyelonephritis 
 DIABETES + NO DIABETES  
PYELONEPHRITIS 17 3 20 
NO 
PYELONEPHRTIS 
46 69 115 
 63 72 135 
 
Table 45. Chronic kidney disease and pyelonephritis 
 CKD + NO CKD  
PYELONEPHRITIS 2 18 20 
NO 
PYELONEPHRTIS 
1 114 115 
 3 132 135 
 
In those with community acquired pneumonia, presence of underlying respiratory illness such 
as chronic obstructive pulmonary disease (COPD) and asthma was not found to be 
statistically significant with the outcome of death. 
In patients with scrub typhus, 29% of patients with shock requiring inotropes died compared 
to 2.3% of patients who did not have shock and this difference was statistically significant (p-
value 0.001) with mortality. The difference in mortality rate between patients with acute  
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kidney injury (AKI), and acute respiratory distress syndrome (ARDS) and those without were 
not significantly different. 
Table 46. Shock and scrub typhus 
 ALIVE DEATH  
NO SHOCK  43 1 44 
SHOCK REQURING 
INOTROPES  
22 9 31 
 65 10 75 
 
There was no statistically significant correlation found with organ dysfunction and mortality 
in those with pyelonephritis 
Table 47 Shock and pyelonephritis 
 ALIVE DEATH  
NO SHOCK  0 0 0 
SHOCK REQURING 
INOTROPES  
12 8 20 
 12 8 20 
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Table 48 Acute kidney injury and pyelonephritis 
 ALIVE DEATH  
AKI present 0  0 
AKI absent 12 8 20 
 12 8 20 
            
Table 49 Shock and community acquired pneumonia 
 ALIVE DEATH  
NO SHOCK  0 0 44 
SHOCK REQURING 
INOTROPES  
7 5 12 
 7 5 12 
 
 
Table 50. Acute respiratory distress syndrome and community acquired pneumonia 
 ALIVE DEATH  
ARDS present 7 5 12 
ARDS absent 0 0 0 
 7 5 12 
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APACHE II score of > 26 was associated with mortality of 60% in scrub typhus compared to 
10.9% with APACHE II score of 11-25 and 12.5% with APACHE II score of <10 and this 
difference was statistically different (0.05). Table APACHE II score and scrub typhus 
Table 51 APACHE II score and scrub typhus 
 ALIVE DEATH  
APACHE II SCORE 
<10 
7 1 8 
APACHE II SCORE 11 
– 25 
49 6 55 
APACHE II SCORE 
>26 
2 3 5 
 58 10 68 
 
APACHE II score of > 26 was associated with mortality of  62.5 % in pyelonephritis 
compared to 20 % with APACHE II score of 11-25 and this difference was statistically 
different (p=0.04) 
Table 52 APACHE II score and pyelonephritis 
 ALIVE DEATH  
APACHE II SCORE 
<10 
0 1 1 
APACHE II SCORE 11 
– 25 
8 2 10 
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APACHE II SCORE 
>26 
3 5 8 
 11 8 19 
 
There was no relationship between APACHE II score and mortality associated with 
community acquired pneumonia probably due to the small number of cases. 
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10. DISCUSSION 
In this prospective and retrospective study of severe community acquired infections requiring 
ICU care we studied 135 patients with almost equal sex distribution and mean age of 53 
years. Diabetes was the most common co-morbid condition in 47% of patients followed by 
hypertension, Ischaemic heart disease and COPD. 20 patients with diabetes died, with a 
mortality rate of 31.7% indicating the severity of the morbidity profile in this patient group. 
In this prospective and retrospective study of severe community acquired infections requiring 
ICU care we studied 135 patients with almost equal sex distribution and mean age of 53 
years. Diabetes was the most common co-morbid condition in 47% of patients followed by 
hypertension, Ischaemic heart disease and COPD. 20 patients with diabetes died, with a 
mortality rate of 31.7% indicating the severity of the morbidity profile in this patient group. 
 
10.1 SPECTRUM AND ETIOLOGY  OF SEVERE COMMUNITY ACQUIRED  
INFECTION 
Our study showed that the three most important community acquired infections 
requiring admission in the medical intensive care unit (MICU) and medical high dependency 
unit (MHDU) were scrub typhus (55.6%), pyelonephritis (14.8%) and community acquired 
pneumonia (8.9%) together occupying 79.3% of the community acquired infections. A wide 
spectrum of infections caused the remaining 20.7% of infections ranging from skin and soft 
tissue infection, meningitis, encephalitis, malaria, enteric fever, bacteremia with unknown 
source, Dengue and undifferentiated febrile illness without identified cause.  
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This was consistent with the study on acute febrile illness by Anugrah et al in2007 
(2). The reasons for such high proportion may be due to the ongoing epidemic, lack of 
disease awareness and high referral rates due to morbidity of the illness and inability of local 
practitioners to diagnose this early. Despite numerous case reports from across the country, 
medical practitioners are still unaware of this disease. Consequently majority of the cases 
presenting with varying degrees of severity are undiagnosed or misdiagnosed. 
      According to Foxman, urinary tract infection accounts for the second most 
common bacterial infection in the United States (52). Though the accurate incidence is not 
available from India, it still accounts for one of the commonest bacterial infections (45, 46, 
50). In none of these studies, the proportion of cases with severe illness was addressed. In our 
study population, 14.8% of the cases were due to pyelonephritis or complicated urinary tract 
infection.  
From the clinico-epidemiological and bacteriological studies conducted in India, 
Escherichia coli  appears to the most common organism isolated from blood and urine culture 
(45,46). Eswarappa et al and Akram et al, in two independent studies reported an incidence of 
ESBL E.coli in 42% of the isolates (45, 46). In our study the most common organism isolated 
from blood culture was E. coli (85%), of which 83.3% was ESBL E. coli. The proportion of 
urine culture isolates of E.coli was 88.9% and 77.8% of these were ESBL E.coli. The 
proportion of extended spectrum beta lactamase (ESBL) producing Escherichia coli as the 
causative agent is showing an increasing trend which is alarming. The resistant strains among 
gram negative bacteria are higher in India as opposed to western countries (107). 
Among the 135 cases, 8.9% was due to severe community acquired pneumonia 
(CAP). In this case as well, there is a paucity of data pertaining to the exact proportion of 
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cases from India. A study by Garibaldi in United States, pneumonia was ranked as the sixth 
commonest cause of death (16).  
In 33.3% of the cases with CAP, a causative organism was isolated from blood 
culture. The rate of isolation of organisms from blood culture in this study was higher than 
that seen in a study by Shah et al (15). However the observed rates in the isolation of 
causative agents from Western literatures varied from 10-33% (110,111). This was consistent 
with the finding in this study, suggesting that one-fourth to one-third of cases are not 
bacteremic (15).  
Isolation of organisms from sputum culture in this study was 25% and was similar to 
the other Indian studies (15). 
Overall the isolation of a causative agent was obtained in 50% of the study population 
which was higher than that reported by Shah et al. Proper collection of the sputum sample, 
from endo tracheal aspirate may have probably contributed to this high rate of isolation. 
However prior use of antibiotics still accounts for the low rates of isolation from blood 
culture (15). 
The most common agent isolated from blood culture in this study was Streptococcus 
pneumoniae, which was similar to the findings in other studies from India (17, 18). The 
isolation of gram negative bacteria in this study was lower compared to other Indian studies.  
The reason for the same is not clear. 
There were 4 cases of bacteremia with unidentified source due to E.coli, Klebsiella 
and Enterobacter. 
In patients with Scrub typhus the Scrub ELISA test was positive in 90.7 % of cases. 
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10.2 ADMISSION CORRELATES AND MORTALITY 
Severe scrub typhus was found to be higher in the elderly age group (>50 years) 
which was consistent with the study by Varghese et al. However neither of the studies 
showed a significant relation between age and mortality (30). This may be because both the 
study population were from the same catchment area, and the index of suspicion in patients 
presenting with  acute febrile illness with MODS is high, thus leading to early initiation of 
appropriate antibiotics.  
Among those with pyelonephritis, the proportion of males was higher in males this 
study contrary to that reported from other Indian studies (45, 46). The reason for this could be 
referral bias, as all female patients with non-severe urinary tract infection would have been 
treated with antibiotics elsewhere. The proportion of males with severe pyelonephritis could 
imply those with benign prostatic hypertrophy, considering that all of them were above 50 
years. 
The proportion of cases with pyelonephritis presenting in patients of age group > 50 
years is consistent with other Indian studies (45). The risk of presenting with severe form of 
the illness was also higher in the elderly. Though a statistical significance was not found, it is 
important to note this finding.  
Diabetes mellitus was seen in 85% of the cases with pyelonephritis and the risk of 
mortality was statistically significant in this group. Long duration of diabetes, poor glycaemic 
control and pre-existing renal dysfunction in older age group are likely to be pre disposing 
factors to develop severe urinary tract infection (51). Considering these factors, prompt 
diagnosis and early initiation of therapy is warranted to reduce the risk of complications and 
mortality. Diabetes was not just a risk factor for pyelonephritis but also for severe scrub 
typhus (32% were diabetic) and community acquired pneumonia (75% were diabetic) 
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75 % of cases with CAP was higher in the elderly age group (>50 years) in this study. 
Contrary to what was seen in the study by Shah et al, elderly age group did not predict 
mortality in this study. In this study population, the presence of underlying lung diseases 
were seen only in 5 cases, but no relation to mortality was found. The smaller sample size 
may be the reason for this. 
Among the cases with scrub typhus, the most common clinical presentation was fever which 
was seen in all cases. The clinical signs and laboratory tests with the highest sensitivity for 
diagnosis of scrub typhus were Eschar (0.84), thrombocytopenia (0.85) and elevated SGOT 
(0.97). The clinical signs with highest specificity for diagnosis of scrub typhus were Eschar 
(1), thrombocytopenia (0.65) and elevated SGOT (0.68). 
These findings are consistent with the studies of Chrispal et al, which showed that 
fever, leucocytosis, thrombocytopenia and elevated liver enzymes correlated with the 
diagnosis of scrub typhus. In this study eschar was noted in 83% of the cases. Though the 
reported incidence of eschar has been variable across studies, this finding is characteristic of 
scrub typhus. So even in the absence of availability of serological studies, diagnosis of scrub 
typhus can be made and treatment may be initiated, and this is likely to reduce the severity of 
the illness (2, 21, 30, 31). 
In patients with pyelonephritis, 12 patients presented with typical features of fever, dysuria 
and renal angle tenderness. In 30% of the cases, altered sensorium was reported in addition to 
the above symptoms. Dysuria had a sensitivity of 1 for diagnosis of pyelonephritis and 
dysuria and renal angle tenderness had specificity of 1 for diagnosis of pyelonephritis. 
This was similar to that reported by Mahesh et al (53%). In this study population all 
20 patients had fever as the presenting illness, while Meyers et al in their study on bacteremia 
Page | 102  
 
in the elderly reported occurrence of fever in 90% of the cases (112). So presence of febrile 
illness with dysuria, and renal angle tenderness is characteristic of pyelonephritis.  
All patients with CAP in this study, had fever and respiratory symptoms of productive cough 
and dyspnea, which was similar to that reported in other Indian studies (15). Though a 
significant correlation was not observed, presence of these clinical symptoms and 
radiological findings of patch characterised community acquired pneumonia in this study 
population. The sensitivity of cough and chest x-ray findings for diagnosis of community 
acquired pneumonia in the ICU was 1 and 0.67 and specificity of chest x-ray for diagnosis of 
community acquired pneumonia was 1. 
Among the organ system failure in scrub typhus, shock requiring vasoactive agents 
significantly correlated with death and this was consistent with the finding reported by 
Varghese et al (30). 
 All patients with pyelonephritis and underlying diabetes mellitus had serum 
creatinine values more than 1.5 g/dl, suggesting the possibility of a pre-existing renal 
dysfunction. However baseline serum creatinine value was not available in these patients. 
10.3 LABORATORY PARAMETERS AND CORRELATION WITH PREDICTING 
DIAGNOSIS 
Presence of fever with eschar helped in making the diagnosis of scrub typhus. This was 
consistent with other studies as well (2, 30). In the absence of eschar, laboratory parameters 
such as leucocytosis and elevated liver enzymes along with fever characterised the diagnosis 
of scrub typhus as reported by Anugrah et al (2). 
 Presence fever with dysuria was not specific for the diagnosis of pyelonephritis. However 
with added clinical symptom of flank pain and isolation of typical organism from either blood 
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or urine culture was characteristic of pyelonephritis. This was consistent with other Indian 
studies (45). 
For the diagnosis of CAP, symptoms of fever with respiratory symptoms alone was not 
specific, especially in the setting of severe illnesses, as dyspnea and cough was seen in other 
infections also, suggesting presence of acute respiratory distress syndrome. However 
radiological features of consolidation or interstitial infiltrates and isolation of typical 
organism either from the blood or sputum help in the diagnosis of CAP (15,16) . 
Acute Physiology and Chronic Health Evaluation II (APACHE II) score is a validated 
clinical severity index used to assess severity of a disease in intensive care unit (109). In this 
study, higher APACHE II score correlated with mortality in patients with scrub typhus and 
pyelonephritis.  
10.4 CHOICE OF ANTIBIOTIC AND APPROPRIATE USE OF ANTI MICROBIAL 
AGENTS IN SCRUB TYPHUS, PYELONEPHRITIS AND CAP 
In all cases of scrub typhus appropriate antibiotic was used, where 72 patients 
received doxycycline. In addition to doxycyline, azithromycin was administered to 63 
patients, with the hypothesis that oral absorption of doxycycline is lower in severe forms of 
scrub typhus. However there are no studies which has looked into the difference in efficacy 
and drug of choice in severe forms of the disease. Except in special situations such as in 
children <8 years, pregnant women, and documented resistance to doxycyline, the drug of 
choice for scrub typhus remains is doxycycline (108). 
95 % of the patients with pyelonephritis received carbapenems (meropenem or 
ertapenem). The appropriate antibiotic of choice in severely ill patients suspected to have 
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pyelonephritis should be carbapenems considering the alarming increase in the rates of 
isolation ESBL E.coli noted in our study as compared to other Indian studies (45).  
In patients with CAP, the choice of antibiotics was varying. In our study population 
the most common micro organism isolated was Streptococcus pneumoniae, which was 
similar to that reported by Bansal et al (19). The appropriate antibiotic of choice should be 
based on the local epidemiology and the susceptibility. In our study, all the strains of 
S.pneumoniae was susceptible to penicillin. 
10.5 MORTALITY RATES AND PREDICTORS OF OUTCOME 
The overall mortality rate in our study was 25.9%. The infection specific mortality rates of 
the three infections were scrub typhus (13.3%), pyelonephritis (40%) and community 
acquired pneumonia (41.7%). However due to the larger number of patients with Scrub 
typhus was the chief cause of death. 
In our study the infection specific mortality rate due to with scrub typhus was 13.3%, but this 
was higher than that reported by Varghese et al in 2010 (30). The reason for the high rates of 
mortality in our study population may be due to selection as our study focussed on patients 
with severe scrub typhus requiring ICU care. 
In our study we were able to show that shock requiring inotropes was found to be a predictor 
of mortality which was similar to that reported by Varghese et al (30).  On bivariate analysis 
presence of eschar, pre-existing medical co- morbidities, acute respiratory distress syndrome, 
and acute kidney injury with serum creatinine > 1.5 g/dl, need for mechanical ventilation did 
not have any statistically significant impact on mortality. In Varghese et al’s study in addition 
to shock, found significant correlation with mortality in patients with acute kidney injury, and 
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acute respiratory distress syndrome. The reason that we were unable to show the same in our 
study may be because of the small sample size. 
In our study all patients with pyelonephritis presented with shock and the mortality rate was 
22.9 %. In a retrospective study, Efthasthiou et al showed that presence of shock was an 
independent predictor of mortality. This is consistent with the finding in our study, however 
since all our patients had shock we were unable to analyse the parameter for the statistical 
significance(112).  
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11. CONCLUSIONS 
 
In our study three community acquired infections presenting with severe illness identified  
were scrub typhus (55.6%), pyelonephritis (14%) and community acquired pneumonia 
(8.9%). Together these infections contributed to 79% of all the community acquired 
infections requiring admission to MICU/MHDU. 
Escherichia coli contributed to 66.7% of all the etiological micro-organisms isolated from 
blood culture and the rate of ESBL E.coli was 55%. Streptococcus pneumoniae (12%) was 
second most commonly isolated organism. 
 Presence of fever and eschar characterized the clinical diagnosis of scrub typhus. Febrile 
illness, with leucocytosis, deranged liver enzymes and leucocytosis can help make the 
diagnosis in addition. 
Fever, upper urinary tract symptoms such as dysuria, and renal angle tenderness, and 
isolation of typical organism either from blood or urine culture, characterise the diagnosis of 
pyelonephritis. 
Fever with cough and breathlessness, with radiological finding of consolidation characterize 
community acquired pneumonia. 
The overall mortality rate was 25.9%. Mortality due to scrub typhus was 13.3%, 
pyelonephritis (40%) and that due to CAP was 41.7% 
The choice of antibiotic for scrub typhus, was doxycycline.  
Additionally azithromycin was also administered in severely ill patients with scrub typhus 
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Considering the alarming rates of ESBL E.coli, empirical therapy for pyelonephritis and 
unidentified source of sepsis with carbapenems is advised. 
 Penicillin and penicillin group of drugs are still the drug of choice in CAP. 
Shock requiring vasoactive agents was an independent predictor of mortality in patients with 
scrub typhus.  
 All patients with pyelonephritis presented with shock and was significant for mortality. 
 Diabetes mellitus was a significant risk factor to develop pyelonephritis. 
As the APACHE II score increased, there was increased risk of poor outcome, as seen in 
patients with scrub typhus and pyelonephritis. 
Based on the clinical profile and microbiology of community acquired infections requiring 
ICU care in this study we suggest the following algorithm for diagnosis and management of 
acute febrile illness admitted to ICU at Christian Medical College, Vellore.  
This algorithm may be beneficial in improving the management of seriously ill community 
acquired infections. 
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                                  Short duration fever with features of SIRS/Shock  
                                                 admitted to MHDU/MICU 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 19.Approach to diagnosis and management of acute febrile illness admitted to 
ICU at Christian Medical College, Vellore 
 
 
Investigations- Complete blood count, LFT, creatinine, Malarial parasite, urine routine 
blood/urine culture, chest X ray, serology for scrub typhus- 
Eschar +/-, 
leucocytosis,  
elevated liver 
enzymes           
Dysuria,   renal 
angle 
tenderness +/-, 
pyuria                   
Cough. Sputum 
production, 
consolidation 
 
Unidentified 
source of sepsis 
Doxycycline with 
Azithromycin+/- 
Carbapenems- 
Inj.meropenem
  
IV Pipericillin- 
tazobactum with 
azithromycin  
Inj Meropenem 
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12. LIMITATIONS 
1) The sample size was small, in view of the patient recruitment in the tertiary care referral 
centre. 
2) Assessment of severity of infection with analysis of blood gases 
3) Study of the economic impact of these infections. 
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ANNEXURE 1 
 
PATIENT INFORMATION SHEET 
TITLE: Clinical spectrum of severe community acquired infections in patients under General 
Medicine requiring admission to medical intensive care unit and medical high dependency 
unit in a tertiary care hospital in South India. 
1) ABOUT THE STUDY: 
You/ your patient are being requested to participate in a study to look at the different kinds of 
infections that are seen in the community. This study looks at the different types of severe 
infections with which people come to hospital.  
We hope to include all the people who come with severe infections to the department of 
General Medicine and then get admitted in medical intensive care unit or medical high 
dependency unit at Christian Medical College in this study. 
2) WHAT ARE THE INFECTIONS WE ARE LOOKING AT? 
We have observed that the common infections with which people come to hospital with 
include pneumonia, urinary tract infection, typhoid, malaria, scrub typhus, dengue fever, and 
other common viral infections. Some of these patients can have severe infections and hence 
come to the hospital in a serious condition. These patients require care in ICU or HDU. 
We hope to study in detail about these infections. In this study we will be studying in detail 
about the signs and symptoms of the infection, the treatment and the outcome of the disease. 
 
3) IF YOU TAKE PART WHAT WILL YOU HAVE TO DO? 
If you /your patient agree to participate in this study, you/ your patient will have to consent 
for the same. All the information relevant to the you/ your patient’s condition will be 
obtained from the Outpatient chart, In patient charts and clinical work station.  
This study will not affect your treatment. All the treatments that you are already on will be 
continued and your regular treatment will not be changed during this study.  
We will not perform extra or un necessary tests or investigations if it is not required for your 
treatment. 
4) CAN YOU WITHDRAW FROM THIS STUDY AFTER IT STARTS? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
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We do not expect any injury to happen to you. 
 Will you have to pay for the study? 
You do not have to pay any money for the study. The treatment that you/ your patient will 
receive during the hospital stay will continue and the expenses involved in the treatment will 
be decided by the hospital. 
  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
 
If you have any further questions, please ask Dr.Betsy Ann Joseph  
Contact details: 
Dr.Betsy Ann Joseph 
New PG Quarters # 2/7 
Christian Medical College  
Vellore 
Tamil Nadu- 632004 
Mob no: 9500528304 
Email: betsyshalom2010@gmailcom 
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ANNEXURE 2 
Study Title: Clinical spectrum of severe community acquired infections in patients under 
General Medicine requiring admission to medical intensive care unit and medical high 
dependency unit in a tertiary care hospital in South India. 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
 
(iii)  I understand that the investigator of this study and, others working on the 
investigator’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current study 
and any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
 
(v)  I agree to take part in the above study. 
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Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
   Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
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Name & Address of the Witness: ______________________________ 
 
ASSENT FORM 
Christian Medical College, Vellore 
Department of General Medicine 
 
Clinical spectrum of severe community acquired infections in patients under General 
Medicine requiring admission to medical intensive care unit and medical high 
dependency unit in a tertiary care hospital in South India. 
 
 
We are doing a research study on people with severe infections that get admitted in the 
intensive care unit in our hospital. Research is a way to learn more about various things for 
example in this case we are studying about infections. 
Infections are diseases that are caused by microorganisms. We have observed that some 
people who have severe infections require special care and they require to be in intensive care 
units. Intensive care unit is that part of the hospital where very sick patients are kept. 
We will be studying in detail about these infections. The problems that these infections cause 
to people, the treatment and the end result of the same. 
 If you decide that you want to be part of this study, you will be asked to give details about 
your problems. The good thing is that we will not be doing any un necessary tests or 
additional tests. Our study will not affect your treatment. 
If you do not want to be in this research study, you are free to do so. 
When we are finished with this study we will write a report about what was learned.  This 
report will not include your name or that you were in the study. 
 
You do not have to be in this study if you do not want to be.  If you decide to stop after we 
begin, that’s okay too.  Your parents know about the study too. 
 
If you decide you want to be in this study, please sign your name. 
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I, _________________________________, want to be in this research study. 
 
               (Sign your name here)                                   (Date) 
If you have any further questions, please ask Dr.Betsy Ann Joseph  
Contact details: 
Dr.Betsy Ann Joseph 
New PG Quarters # 2/7 
Christian Medical College  
Vellore 
Tamil Nadu- 632004 
Mob no: 9500528304 
Email: betsyshalom2010@gmailcom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 125  
 
ANNEXURE 3 
 
 
 
SEVERE COMMUNITY ACQUIRED INFECTIONS NEEDING ICU/HDU CARE  
DATA ABSTRACTION FORM 
Name:       Age:    Sex: Male / Female 
Address:  
 
Contact number:        
PRIMARY ADMISSION    /     RE-ADMISSION 
Date of hospital admission:      
Date of ICU admission:    Discharge date: 
Day of illness: 
Admission diagnosis: 
Final diagnosis: 
 
Risk factors/Co-morbidities: (Circle features present at admission) 
Asthma COPD Other chronic lung disease 
Diabetes Ischaemic heart disease Chronic heart failure 
Rheumatic heart disease Chronic renal failure Chronic liver disease 
Steroid use >3 months Immunosuppressive therapy HIV infection 
Pregnancy Seizure disorder Smoking 
Morbid obesity Auto immune diseases  
  
 
Symptomatology at presentation: (Circle features present at admission and list duration) 
Symptomatology Duration of symptom Symptomatology Duration of symptom 
Serial No: Hosp. No: 
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Fever   Breathlessness  
Running nose/blocked  Sore throat  
Headache  Myalgia/body pain  
Wheezing  Loose stools  
Focal neurological 
deficits 
 Vomiting  
Seizures  Bleeding 
manifestations 
 
Cough  Altered sensorium  
Dysuria  Flank pain   
 
CLINICAL EXAMINATION 
 
BP:                                                                             HEART RATE 
 
TEMPERATURE:                                                     RESPIRATRY RATE: 
 
SATURATION                                                          SENSORIUM (GCS): E.. V.. M.. 
 
LOCALISING SIGNS 
 
Respiratory system: 
 
Cardiovascular system 
 
Abdomen 
 
 
CNS: 
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Skin and miscellaneous 
 
 
 
INVESTGATIONS 
 
Date  Date    
 WBC COUNTS  Urine culture  
 DIFFERENTIAL 
COUNTS 
 serology  
 Platelets  Scrub typhus  
 haemoglobin  dengue  
 Creatinine   H1N1  
 LFT  Leptospirosis  
 Urine analysis  MP/MF  
 Blood culture  CHEST X RAY  
 FUID ANALYSIS 
(ASCITIC/ 
PLEURAL/ CSF) 
   
 TC    
 DC    
 GLUCOSE  SERUM 
GLUCOSE 
 
 PROTEIN  SERUM 
PROTEIN 
 
 ALBUMIN  SERUM 
ALBUMIN 
 
 LDH  SERUM LDH  
 CULTURE    
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BLOOD GAS ANALYSIS 
pH   
Pco2   
Po2   
BE   
Bicarb   
lactate   
Fi O2   
PF ratio   
 
Treatment details: (antibiotics)  
Drug Dose Date started Date stopped Duration 
     
     
     
     
     
     
     
     
     
 
ADMISSION SCORE- APACHE III 
 
Ventilation and renal replacement therapy data: 
Ventilated: Yes / No Non-invasive ventilation: Yes / No Invasive: Yes / No 
Duration of ventilation (invasive) days: 
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Need for muscle relaxants: Yes / No   Duration of relaxants:  
Tracheostomy: Yes / No 
Time from intubation to tracheostomy (days): 
 
Dialysis done: Yes / No   Day of initiation:  Type:  
Duration of dialysis:  
 
Inotropes:   yes/no 
Choice of inotropes: dopamine/noradrenaline/adrenaline/vasopressin/others (specify) 
Number of days: 
 
 
Nosocomial infections: 
Type Yes / No If yes, day Organism (s) Treatment 
VAP 
 
Yes / No    
CRBSI 
 
Yes / No    
Uro-sepsis Yes / No    
Other infections 
 
  
Yes / No    
 
Other complications: 
Seizures Myocarditis Pulmonary embolism  
Decubitus ulcers GI bleed   
 
Duration of ICU stay (days):    Duration of hospital stay (days): 
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ICU outcome:  Dead / Alive / Discharged at request/ PVS   
 
Hospital outcome:  Dead / Alive / Discharged at request / PVS 
 
Probable cause (s) of death: 
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ANNEXURE 4 
DATA WORK SHEET 
retrospective/prospectiveHosp.No. Age Sex days- total hospital stay Days-ICU
R 657997F 32 1 7 4
R 664673F 73 1 6 6
R 630936F 65 0 6 5
R 534247D 53 0 8 4
R 657019F 25 0 5 2
R 713176F 47 0 7 5
R 585364C 30 0 42 15
P 912219F 75 1 11 10
R 696024F 50 0 10 7
P 922578F 47 1 13 3
R 441600F 52 1 2 2
R 389037F 64 1 12 7
R 401660F 30 1 12 7
P 917471F 75 0 58 7
P 922084F 87 1 21 21
R 740773F 40 1 20 10
R 726303F 24 0 10 7
R 611403F 35 0 20 4
R 618582F 57 1 13 7
R 623512F 65 1 26 8
R 688915F 56 0 11 6
P 917357F 65 1 2 2
P 922562F 68 0 11 9
P 926835F 62 0 17 3
P 923778F 45 1 14 7
R 604763F 50 1 15 9
R 696497F 22 0 7 5
R 750101F 60 0 19 10
R 657814F 31 1 11 2
P 159506f 52 0 12 5
P 054566F 74 1 9 5
P 063519G 45 0 11 7
R 675012F 60 1 5 5
R 562477B 71 0 4 3
R 688462F 77 1 2 2
R 675288F 28 1 21 8
R 750340F 48 0 25 15
P 750778F 28 0 22 2
R 740678F 55 0 11 8
P 751783F 45 1 8 4
R 720214F 55 1 30 28
R 445501C 67 1 10 9
R 598904 68 1 16 9
P 751571F 74 1 11 11
P 308044C 74 1 40 5
R 190391C 64 1 7 3
R 675091F 50 0 2 2
R 865765D 86 1 2 2
R 696282F 41 0 10 3
R 379593F 65 1 17 16
R 384175F 85 1 2 2
R 696092F 25 1 10 5
R 384030F 40 1 10 5
R 384358F 19 1 2 2
R 611505F 65 1 7 6
R 740299F 65 0 12 7
R 820816D 57 1 3 3
R 713506F 18 1 10 8
R 623586F 17 1 3 3
R 282088B 58 1 9 2
P 917382F 23 1 1 1
R 448439F 16 0 7 2
R 849453C 55 1 17 2
P 630509D 62 0 10 7
P 914041F 64 1 10 3
P 914812F 19 1 11 6
R 389565F 49 0 10 5
R 691285F 55 1 11 7
R 713689F 62 0 7 3
P 917379F 48 0 12 7
R 441367F 43 0 13 9
R 384603F 78 0 8 6
R 384659F 34 1 12 8
R 361235F 35 1 6 2
R 379930F 37 1 5 1
R 379063F 42 0 12 6
R 394265F 54 0 8 5
R 415118F 60 0 22 15
R 406100F 63 1 10 5
R 491258C 57 0 8 4
R 639809F 78 1 7 3
R 426570A 70 0 17 14
R 671589F 32 1 12 9
R 688880F 60 1 2 2
R 696423F 63 1 8 5
R 704375F 60 1 11 8
R 329399D 50 0 31 19
R 696813F 32 1 31 21
R 509060F 40 1 14 4
R 740541F 19 0 13 8
R 657912F 45 0 11 7
R 675877F 55 0 7 3
P 751582F 69 0 12 5
P 751493F 59 1 9 5
P 753826F 63 1 9 3
R 389619F 52 0 6 3
R 664501F 72 1 10 3
R 726988F 40 1 7 4
R 713324F 48 1 5 5
R 361362F 48 0 8 5
R 639822F 82 0 9 5
R 720149F 72 1 9 7
R 361362F 48 0 8 5
R 639822F 82 0 9 5
R 720149F 72 1 9 7
R 720153F 42 1 8 5
R 750308F 40 1 8 6
R 675222F 69 0 9 9
R 508484F 30 0 3 3
R 675057F 68 1 5 5
R 379510F 64 1 8 4
R 999978D 53 0 10 7
P 933061D 44 0 8 6
R 750078F 65 0 4 4
R 379729F 43 0 15 12
R 688956F 70 0 6 4
R 688844F 68 1 10 2
R 726836F 38 1 7 2
R 696067F 41 0 8 5
R 713226F 51 1 8 4
R 657690F 24 0 16 6
P 799060F 37 0 8 3
R 696571F 58 1 9 6
R 675855F 65 1 1 1
P 922815F 40 0 7 5
R 485648F 47 0 15 4
R 651965F 67 1 8 7
R 704229F 65 0 8 7
R 704766F 72 1 10 9
R 743979D 59 0 3 3
R 350929F 54 0 12 6
P 366124F 68 1 15 7
P 750738F 55 0 24 4
R 977663D 55 0 7 7
R 415467F 55 1 20 8
OUTCOME APACHE II FINAL DIAGNOSIS
2 10 1
2 23 6
2 23 3
2 18 1
2 999 1
2 24 1
2 11 4
1 28 1
2 32 1
2 6 4
1 999 8
2 23 12
2 999 13
1 31 3
2 41 3
2 14 6
2 22 1
2 26 1
2 19 9
1 25 7
2 22 1
1 999 8
2 14 1
1 24 1
2 12 1
1 30 9
2 3 1
2 25 8
2 5 8
2 20 3
2 18 3
2 9 10
1 28 3
1 34 8
1 40 8
2 15 8
2 27 6
2 11 1
2 25 8
2 20 1
1 16 9
1 24 3
1 10 3
1 13 6
2 22 6
2 999 6
1 999 6
1 999 6
2 20 6
1 24 6
1 999 6
2 10 10
2 13 10
1 999 9
1 30 7
2 19 6
1 999 7
2 11 1
1 999 4
2 10 7
1 999 2
2 999 13
2 13 3
2 15 3
2 37 3
2 11 11
2 15 1
2 14 1
2 999 1
2 17 1
1 11 1
2 21 1
2 15 1
2 999 1
2 999 1
2 23 1
2 17 1
2 12 1
2 999 1
2 18 1
2 17 1
1 19 1
2 6 1
1 27 1
2 24 1
2 23 1
2 11 1
2 16 1
2 19 1
2 21 1
2 16 1
2 12 1
2 19 1
2 13 1
2 11 1
2 999 1
2 20 1
2 7 1
1 19 1
2 13 1
2 21 1
2 22 1
2 13 1
2 21 1
2 22 1
2 17 1
2 18 1
2 20 1
1 16 1
1 31 1
2 14 1
2 18 1
2 25 1
1 24 1
2 9 1
2 17 1
2 14 1
2 12 1
2 22 1
2 10 1
2 11 1
2 8 1
2 35 1
1 9 1
2 14 1
2 25 3
1 34 3
1 32 3
1 33 3
2 22 3
2 27 3
1 15 3
2 14 11
2 32 3
2 19 3
Organ system failure- respiratory system
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
11
2
2
1
1
1
1
1
1
2
1
1
2
1
1
2
1
1
1
1
1
1
1
1
2
1
1
1
1
1
2
1
2
1
1
1
1
1
2
1
1
1
1
1
1
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
organ system failure- cardiovascular
2
1
1
1
2
1
2
1
1
2
1
1
1
1
1
2
2
1
1
1
2
1
1
1
2
2
2
2
2
2
2
2
1
1
1
1
2
1
2
2
2
2
1
2
1
2
2
2
2
11
2
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
1
2
1
2
1
2
2
2
2
2
1
1
2
2
1
1
1
2
1
2
2
2
1
2
1
1
2
1
21
2
1
2
1
2
2
1
2
2
2
1
1
1
2
2
2
1
2
2
2
2
2
2
2
2
2
1
2
2
2
2
2
1
2
2
2
1
2
Organ system failure-renal treatment- ventilation
2 1
2 1
1 2
2 2
2 2
1 1
2 1
1 1
1 1
2 0
1 1
1 1
1 1
1 1
1 1
2 1
2 1
2 1
1 1
2 1
2 1
1 1
2 1
1 1
1 1
1 1
2 0
1 1
1 0
1 1
1 1
2 2
1 1
1 1
1 1
1 1
1 1
1 2
1 1
1 1
2 1
1 1
1 1
1 2
1 1
1 1
1 1
1 1
2 2
1 1
1 1
2 0
1 1
1 1
1 1
2 1
2 1
2 1
2 1
2 0
1 1
2 1
1 2
1 1
1 1
2 0
2 2
1 1
2 2
1 1
2 1
1 1
1 1
2 1
1 2
1 1
1 1
1 1
1 1
2 2
1 0
1 1
2 0
1 1
2 2
2 1
1 1
1 1
1 0
1 1
2 1
1 2
1 1
1 1
2 1
2 2
1 1
2 2
1 1
2 2
2 1
1 1
2 2
2 1
1 1
1 1
1 1
2 1
2 1
1 1
1 1
2 1
1 1
1 1
1 1
1 1
1 1
2 2
1 1
1 1
1 1
2 2
1 1
1 1
1 2
1 2
1 1
1 1
1 1
1 2
1 1
1 1
1 1
1 1
1 1
number of days- ventilation treatment-.INOTROPE treatment-dialysis
5 2 2
6 1 2
4 1 2
1 1 2
3 2 2
5 1 2
10 2 2
11 1 2
5 1 2
2 2
1 1 2
6 1 2
6 1 2
7 1 1
21 1 1
6 1 2
8 1 2
3 1 2
7 1 2
7 1 2
5 1 2
3 1 2
7 1 2
2 1 2
6 1 2
8 1 2
1 2
8 1 1
1 2
3 1 2
2 1 2
5 1 2
5 1 1
2 1 1
2 1 2
3 1 1
14 1 1
1 1 2
7 1 2
3 2 2
27 1 2
7 1 1
5 1 2
9 1 2
4 1 2
2 1 2
1 1 2
2 1 2
1 1 2
10 1 1
1 1 2
2 2
7 1 1
1 1 2
7 1 1
6 1 2
2 1 2
7 1 2
2 1 2
1 2
1 1 2
2 2 2
1 1 2
6 1 2
3 1 2
1 2
3 1 2
4 1 2
2 1 2
6 1 2
6 2 2
2 1 2
4 1 1
6 1 2
2 1 2
4 1 2
4 1 2
9 1 2
2 2 2
2 2 2
2 2
14 1 2
1 2
2 1 2
1 2 2
6 1 2
23 1 2
21 1 2
1 1
7 1 2
7 1 2
1 1 2
3 1 1
6 1 2
4 1 2
2 2 2
2 1 1
2 1 2
4 1 1
4 1 2
4 1 2
5 1 2
4 1 2
4 1 2
5 1 2
4 1 2
3 1 2
9 1 2
3 1 2
5 1 1
5 1 2
5 1 2
3 1 2
4 1 2
7 1 2
3 1 2
2 1 2
2 2 2
4 1 2
2 1 2
5 1 2
2 1 2
6 1 2
1 1 2
3 2 2
3 1 1
6 1 1
6 1 1
7 1 1
2 1 2
4 1 1
5 1 2
3 1 1
7 1 1
8 1 2
COMPLICATIONS FEVER BREATHLESNESS COUGH
0 1 2 2
0 1 1 1
0 1 1 2
0 1 1 2
0 1 1 1
0 1 1 2
2 1 2 2
0 1 1 2
0 1 1 2
0 1 2 2
0 1 1 1
0 1 1 2
3 1 1 2
3 1 1 2
1 1 1 2
1 1 1 1
1 1 1 1
1 1 1 1
0 1 1 2
3 1 1 2
0 1 1 2
0 1 1 2
1 1 1 1
4 1 1 1
1 1 1 1
1 1 1 1
0 1 1 1
1 1 1 1
0 1 1 1
0 1 1 2
0 1 1 2
0 1 1 1
0 1 1 2
0 1 1 1
0 1 1 1
1 1 1 1
2 1 1 1
1 1 1 1
0 1 1 2
0 1 1 2
1 1 1 2
1 1 1 1
1 1 1 1
8 1 1 1
1 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
1 1 1 1
0 1 1 1
5 1 1 1
0 1 2 2
0 1 1 2
0 1 1 2
0 1 1 1
0 1 1 1
1 1 1 1
0 1 1 2
0 1 2 2
0 1 1 1
0 1 2 2
0 1 1 2
0 1 1 1
0 1 1 2
0 1 2 2
0 1 1 2
0 1 1 1
0 1 1 2
1 1 1 2
1 1 1 1
0 1 1 1
1 1 1 1
0 1 1 1
0 1 1 2
2 1 1 1
0 1 1 2
2 1 2 2
0 1 1 1
0 1 1 1
0 1 2 2
1 1 1 1
0 1 1 1
0 1 1 1
0 1 1 2
2 1 1 1
1,3 1 1 1
3 1 1 1
0 1 1 1
1 1 1 1
0 1 1 1
0 1 1 1
4 1 1 2
0 1 1 2
0 1 1 2
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
1 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 1
0 1 1 2
0 1 1 1
3 1 1 2
0 1 1 1
0 1 1 1
0 1 1 1
2 1 1 1
0 1 1 1
0 1 1 2
0 1 1 1
0 1 1 1
0 1 2 2
0 1 2 2
0 1 1 2
3 1 1 2
0 1 1 2
0 1 1 2
1 1 1 2
0 1 1 2
0 1 1 2
0 1 2 2
DYSURIA FLANKPAIN ESCHAR DIABETES MELLITUS HYPERTENSIONCHRONIC OBSTRUCTIVE PULMONARY DISEASE
2 2 2 2 2 2
2 2 2 2 1 1
1 1 2 1 2 2
2 2 2 1 1 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 2 2 2 2
2 2 1 2 2 2
2 2 2 2 2 1
2 2 2 1 1 2
2 2 2 2 2 2
2 2 2 1 1 2
2 2 2 2 2 2
1 1 2 1 1 2
1 1 2 1 1 2
2 2 2 1 2 2
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 1 1 1
2 2 2 1 1 2
2 2 1 1 1 2
2 2 2 1 2 2
2 2 1 1 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 2 2 2 2
2 2 1 2 2 2
2 2 2 1 1 1
2 2 2 2 2 2
1 2 2 2 2 2
1 2 2 2 2 2
2 2 2 1 1 2
1 2 2 1 1 2
2 2 2 1 1 2
2 2 2 1 1 2
2 2 2 2 1 2
2 2 2 1 1 2
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 1 1 2
2 2 2 2 2 2
1 2 2 1 2 2
1 2 2 1 1 1
2 2 2 1 1 1
2 2 2 1 1 2
2 2 2 1 1 2
2 2 2 1 2 2
2 2 2 1 1 2
2 2 2 2 2 2
2 2 2 2 2 1
2 2 2 1 2 2
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 1 2 2
2 2 2 1 1 1
2 2 2 1 1 2
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 1 1 2
2 2 2 2 2 2
2 2 2 2 2 2
1 1 2 1 1 2
1 1 2 1 1 2
1 1 2 1 1 2
2 2 2 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 1 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 1 1 2
2 2 1 2 2 2
2 2 2 2 2 2
2 2 1 2 2 2
2 2 2 1 2 2
2 2 1 2 2 2
2 2 1 1 1 2
2 2 1 2 2 2
2 2 1 1 2 2
2 2 2 2 1 2
2 2 1 1 1 2
2 2 1 2 2 2
2 2 1 1 1 2
2 2 2 1 2 2
2 2 1 1 2 2
2 2 1 2 1 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 1 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 1 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 1 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 1 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 1 2 2 2
2 2 2 2 2 2
2 2 1 2 2 2
1 1 2 1 1 2
1 1 2 1 2 2
1 1 2 1 1 2
1 2 2 1 1 2
1 1 2 1 1 2
1 1 2 1 1 2
1 2 2 1 1 2
2 2 2 1 1 2
1 2 2 2 2 2
1 1 2 1 1 2
ASTHMA chronic kidney diseasechronic kidney disease_rSBP- mmHg DBP-mmHg HR- /min RR- /min SaO2-%
2 2 no 100 70 82 32 92
2 2 no 90 60 118 44 81
2 2 no 100 60 112 38 88
2 2 no 94 60 115 32 90
2 2 no 100 70 120 39 92
2 2 no 90 70 122 44 88
2 2 no 110 70 98 22 99
2 2 no 90 76 120 38 82
2 2 no 100 50 124 55 80
2 2 no 116 70 88 20 92
2 2 no 80 40 132 44 60
2 2 no 90 70 112 22 99
2 2 no 80 60 100 22 95
2 2 no 40 10 122 55 60
2 2 no 120 60 122 44 78
2 2 no 104 60 104 42 88
2 2 no 100 60 144 62 78
2 2 no 80 40 122 32 88
2 2 no 80 60 119 27 93
2 2 no 60 30 124 38 80
2 2 no 60 40 132 39 82
2 2 no 50 20 134 44 76
1 2 no 100 70 108 32 94
2 2 no 102 82 110 28 92
2 2 no 100 72 108 38 90
2 2 no 50 20 112 29 82
2 2 no 90 50 112 28 91
2 1 yes 88 40 117 29 91
2 2 no 100 70 90 22 96
2 2 no 98 60 122 27 91
2 2 no 84 40 123 29 92
2 2 no 90 70 109 27 93
2 2 no 60 20 128 40 99
2 2 no 70 40 132 29 73
2 2 no 90 70 122 35 91
2 2 no 110 70 120 28 90
2 2 no 100 60 120 44 88
2 2 no 80 30 132 32 90
2 2 no 110 82 102 32 93
2 2 no 100 68 102 28 90
2 2 no 90 60 120 29 96
2 2 no 100 60 120 32 92
2 2 no 90 70 122 32 90
2 2 no 92 50 120 28 91
2 2 no 70 20 123 40 89
2 2 no 90 60 108 38 88
2 2 no 80 40 132 34 91
2 2 no 60 20 120 44 81
2 2 no 104 70 120 34 91
2 2 no 90 60 118 44 80
1 2 no 90 40 110 42 88
2 2 no 102 60 110 24 99
2 2 no 92 44 112 34 88
2 2 no 90 62 110 28 94
2 2 no 100 60 119 27 92
2 2 no 90 70 100 28 94
2 2 no 90 70 102 32 99
2 2 no 90 60 120 32 92
2 2 no 100 60 110 22 96
2 2 no 90 40 110 28 94
2 2 no 90 60 110 29 90
2 2 no 92 60 109 32 92
2 2 no 100 70 116 32 99
2 2 no 90 60 118 21 91
2 2 no 98 58 88 25 88
2 2 no 90 60 99 30 79
2 2 no 100 60 109 38 88
2 2 no 80 60 112 29 100
2 2 no 90 60 113 30 90
2 2 no 90 60 120 27 90
2 2 no 90 60 113 28 90
2 2 no 80 60 110 44 94
2 2 no 102 60 90 32 96
2 2 no 90 72 108 32 93
2 2 no 94 62 100 28 98
2 2 no 90 60 130 29 95
2 2 no 90 60 112 32 94
2 2 no 100 70 110 32 94
2 2 no 100 70 110 28 88
2 2 no 80 40 124 40 90
2 2 no 94 48 88 38 95
2 2 no 100 64 132 28 94
2 2 no 90 50 112 26 90
2 2 no 90 58 100 27 94
2 2 no 100 70 122 22 96
2 2 no 100 80 100 26 93
2 2 no 90 60 112 22 90
2 2 no 100 70 110 30 94
2 2 no 100 70 110 34 96
2 2 no 90 60 88 28 93
2 2 no 100 70 118 29 98
2 2 no 104 60 88 32 95
2 2 no 108 70 99 32 94
2 2 no 90 60 109 21 90
2 2 no 90 50 112 25 94
2 2 no 90 40 113 30 96
2 2 no 106 60 120 38 93
2 2 no 80 60 132 29 90
2 2 no 110 68 102 30 94
2 2 no 90 70 102 27 96
2 2 no 90 60 120 32 93
2 2 no 100 70 120 32 98
2 2 no 90 70 102 27 96
2 2 no 90 60 120 32 93
2 2 no 100 70 120 32 98
2 2 no 104 60 122 21 95
2 2 no 100 70 120 25 94
2 2 no 90 60 123 29 94
2 2 no 90 50 108 32 88
2 2 no 90 40 132 32 90
2 2 no 90 60 120 21 96
2 2 no 100 70 113 25 93
2 2 no 104 60 110 30 98
2 2 no 100 70 90 38 95
2 2 no 90 60 108 29 88
2 2 no 104 60 100 30 90
2 2 no 80 68 130 25 96
2 2 no 110 58 90 27 96
2 2 no 90 70 122 32 98
2 2 no 104 60 90 32 94
2 2 no 100 70 112 21 93
2 2 no 92 60 113 25 94
2 2 no 104 60 110 22 94
2 2 no 80 60 113 39 88
2 2 no 110 70 110 35 90
2 1 yes 90 70 90 27 96
2 1 yes 90 40 100 33 87
2 2 no 92 60 113 26 93
2 2 no 100 70 110 27 98
2 2 no 104 60 90 22 95
2 2 no 100 70 108 26 94
2 2 no 90 60 100 22 95
2 2 no 90 50 130 30 92
2 2 no 90 40 123 34 99
2 2 no 90 50 108 32 96
antibiotics WBC HB PLATELET CREATININESGOT SGPT BLOOD CULTURE
1,5,8 11300 12.4 116000 0.66 161 128 0
2,3 12300 11.9 125000 1.07 27 21 0
3,4,7 28400 12 76000 4.05 125 74 1
1,2,3 6700 9.8 20000 1.09 165 49 0
2 11100 9.6 118000 1 47 10 0
1,2 15800 10.5 17000 3.47 253 55 0
1,5.6 7800 13.2 163000 0.63 50 42 0
1,2 8400 8 20000 4.52 109 27 0
1,2 9300 13.4 86000 2 194 97 0
1,2,5,6 11300 11.8 275000 1.01 48 18 0
1,2,4 15700 9 10000 5.16 124 24 0
1 20300 15.2 177000 2.62 52 27 0
5,6 36500 13.4 209000 2.69 48 27 0
4,9,10 28700 10 9000 6.83 141 49 1
4,11,12 23400 10.4 352000 6.84 24 34 0
4,11,13 10100 10 346000 0.66 17 14 0
2,3,4,11 2400 9 5000 0.55 228 41 0
1,2,11,13 5900 9.9 38000 1.04 133 67 0
4,14 15500 11.2 110000 2.22 57 13 1
4,14,15 24300 10.8 409000 1.32 139 66 1
1,2,4 13200 6.1 41000 1.35 39 14 0
4 18200 12 176000 2.3 30 12 0
1,2 13200 12 4000 0.53 138 63 0
1,2,4 14300 13.7 14000 4.38 221 81 0
1,2,4,11 17800 16 14000 1.89 134 88 0
4,14 900 13.7 109000 1.99 793 300 1
2 10500 10 5000 0.7 96 61 0
2,4 12700 8 132000 3.01 28 6 0
1,5 13500 12.1 251000 1.8 317 133 0
4 11400 11 117000 2 126 38 1
4 8200 10.5 137000 2.2 128 33 1
2 6200 10 71000 0.99 150 110 0
1,4 11400 14 22000 5.15 310 242 1
2,4 6000 12 53000 2.77 77 35 0
2,3 10900 7 86000 2.48 536 206 0
4 153000 9 161000 6.18 18 10 0
3,4 9800 11.5 18000 1.9 162 193 1
1,2,4 8000 9 30000 2.86 41 30 0
1,2,5 7600 13.4 15000 3 109 72 0
1,2 10300 13 57000 2.3 60 26 0
4 12100 13 169000 1.08 22 25 1
1,2,4 16800 8.6 76000 1.7 52 26 0
1,4 17000 7.7 90000 1.98 20 7 1
3,4,12 57200 11 500000 2.2 37 23 1
4,12 7700 12 208000 2.53 21 12 1
2,3 13500 11 213000 2.57 57 11 0
3 21500 13 154000 2.65 43 33 0
4 18100 13 313000 2.79 50 14 0
3,16 17300 14 109000 1.01 21 22 0
2,3,12 13700 14 236000 1.53 32 1 1
2,3 26000 13 267000 3.15 361 106 0
1,3 5000 6.8 7000 1.28 800 324 0
1,4,3 9300 15 47000 2 166 91 0
1,3 8900 15 11000 2 726 141 1
4,12,15 15300 12 178000 4.4 262 122 0
1,2 15600 9 272000 0.79 14 12 0
4,15 18800 9.7 48000 1.7 42 40 1
1,4 8400 14 38000 1.15 243 80 0
5,6 12000 14 162000 1.14 86 16 0
4,12 17800 12 226000 0.99 24 12 1
1,5,8 4050 7.7 9000 4 45 19 0
3 10600 12 146000 0.93 40 12 0
4 14200 13 78000 4.53 21 7 1
3,16 11200 12 300000 2.9 29 7 1
4 15500 6 333000 4.87 57 22 1
4 4600 12 85000 0.85 98 37 1
1,3 13400 7 29000 1 138 27 0
1,2 6400 12 82000 1.6 111 65 0
1,2 10800 8 65000 0.7 152 49 0
1,2 6650 10 33000 2.7 344 64 0
1,2,11,13 9500 9.2 16000 0.95 129 31 0
1,4 5700 9.7 53000 3.12 68 41 0
1,4,11
10900 12 48000 6.44 335 88 0
1,2 9500 12 34000 1.3 81 60 0
1,2 9800 15 112000 2.9 132 80 0
1,2 12900 12 57000 2 114 99 0
1,2 21500 9.8 142000 2.53 108 27 0
1,2 16100 11 11000 1.5 292 188 0
1,2 11100 12 37000 2.4 117 54 0
1,2 10000 10 34000 1 158 79 0
1,2 12100 13 160000 3.15 77 89 0
1,2 16600 11 40000 2.16 77 89 0
1,2 22700 16 10000 1.2 505 200 0
1 27400 14 31000 1.9 512 176 0
1,2 7300 13 67000 1.3 102 76 0
1,2 6600 11 59000 1.06 69 29 0
1,2 11000 10 40000 2 89 49 0
1,2,12 102000 14 59000 3.2 163 75 0
1,2,4 4200 12 45000 8 298 80 0
1,2 6700 10 76000 2.45 98 51 0
1,2 12800 9 7000 1.3 104 66 0
1,2 7000 9 57000 1.97 35 20 0
1,2 19000 11 3000 9.44 182 62 0
1,2 8300 11 75000 2 55 33 0
1,2 10400 12 109000 1.18 95 54 0
1,2 5000 10 58000 0.7 174 38 0
1,2 9900 13 151000 4.5 65 51 0
1,2 9100 12 45000 0.52 74 99 0
1,2 15100 16 10000 4 292 71 0
1,2 9900 11 3000 1.05 77 45 0
1,2 19800 11.4 87000 1.05 91 35 0
1,2 15800 12.6 54000 1.7 55 12 1
1,2 9900 11 3000 1.05 77 45 0
1,2 19800 11.4 87000 1.4 91 35 0
1,2 15800 12.6 54000 1.7 55 12 1
1,2 8400 13 101000 3.22 77 39 0
1,2 11000 12 12000 2 225 98 0
1,2 7000 11 16000 1.19 291 60 0
1,2 13400 10 54000 0.85 80 77 0
1,2 23300 8.6 18000 4.28 107 22 0
1,2 8100 12.9 81000 3.16 88 77 0
1,2 7600 11 185000 1.24 77 29 0
1,2 14880 11 91000 2.52 115 46 0
1,2 5300 12,5 10000 2.14 140 25 0
1,2 16300 14 110000 2 96 104 0
1,2 13600 13.2 31000 2.72 64 6 0
1,2 11800 10 52000 1.59 271 86 0
1,2 14300 14 12000 1.04 93 105 0
1,2 8500 11.9 36000 1.96 201 124 0
1,2 10200 13 18000 2.22 109 39 0
1,2 8700 11 47000 2.72 180 142 0
1 8300 13 137000 1.2 185 54 0
1,2,4 215000 19 41000 2.72 226 93 0
1,4 10100 12.6 39000 4 250 60 0
1 14500 11 28000 2 155 61 0
4,11,13 11700 12.2 89000 5.33 18 11 1
4 34800 11 129000 9 62 55 1
4 9100 10 83000 4.98 20 11 1
7,9 13300 11 88000 3.99 18 7 1
4 26100 9.6 164000 2.53 1416 521 1
4 29700 8.1 795000 8.65 11 10 1
4,12 25400 7.3 657000 1.63 31 10 1
3,5 11000 17 194000 1.94 524 137 1
4 14900 9 272000 5.01 40 19 1
3,4 7100 10 109000 3.16 55 23 1
BLOOD CULTURE-ORGANISMchest X ray_SCRUB SEROLOGYurine cultureURINE CULTURE ORGANISM
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
2 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 0 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 0 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
2 no patch 9999 1 2
9999 no patch 9999 1 3
9999 patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
1 no patch 9999 9999 9999
3 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 0 9999
3 no patch 0 9999 9999
9999 no patch 1 9999 9999
9999 no patch 0 9999 9999
9999 no patch 1 9999 9999
2 no patch 0 1 2
2 no patch 9999 9999 9999
9999 no patch 0 9999 9999
2 no patch 9999 1 2
9999 no patch 0 0 9999
9999 no patch 9999 9999 9999
9999 no patch 0 0 9999
5 patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
1 no patch 9999 0 9999
9999 no patch 0 1 2
3 no patch 9999 1 3
5 patch 9999 9999 9999
5 patch 9999 9999 9999
9999 patch 9999 9999 9999
9999 patch 9999 9999 9999
9999 patch 9999 9999 9999
9999 no patch 9999 9999 9999
13 patch 9999 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 0 9999 9999
6 no patch 0 0 9999
9999 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
2 no patch 9999 0 9999
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
5 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 0 9999 9999
2 no patch 9999 1 2
2 no patch 9999 1 2
2 no patch 9999 1 2
10 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
2 no patch 9999 1 2
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
2 no patch 9999 1 2
9999 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 1 9999 9999
9999 no patch 9999 9999 9999
9999 no patch 9999 9999 9999
2 no patch 9999 1 2
2 no patch 9999 1 2
2 no patch 9999 1 2
2 no patch 9999 1 2
1 no patch 9999 1 1
2 no patch 9999 1 2
2 no patch 9999 1 2
12 no patch 9999 9999 9999
2 no patch 9999 1 2
1 no patch 9999 1 1
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